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ABSTRACT OF THE DISSERTATION
Role of Astrocyte Network in Edema after Juvenile Traumatic
Brain Injury
by
Andrew Minoru Fukuda
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, September 2014
Dr. Jerome Badaut, Chairperson

Juvenile traumatic brain injury (jTBI) is the leading cause of death and disability
in young children and adolescents. Despite its lasting detrimental effects on the
developing brain, no pharmacological treatment exists. One of the pathological hallmarks
of jTBI is edema. Astrocytes play a key role in the edema process, and have been
hypothesized that numerous astrocyte networks allow communication and propagation of
edema and secondary injury spread. Two key astrocyte proteins are hypothesized to have
a central role in the edema process: Aquaporin 4 (AQP4) and Connexin 43 (Cx43). AQP4
is expressed extensively in astrocyte endfeet, which surrounds the blood vessels as part of
the blood brain barrier (BBB). Cx43 is central in astrocyte to astrocyte connection and
communication. We hypothesized that AQP4 acted as one of the potential passageway of
water into the astrocyte, whereas Cx43 acted as the bridge between astrocytes once inside
the brain. By blocking these strategically located pathways, we hypothesized that edema
would decrease post-jTBI. In order to achieve specific inhibitions of APQ4 or Cx43, we
utilized small interference RNA (siRNA), which is also an endogenous mechanism.
We observed that after jTBI both AQP4 and Cx43 was significantly upregulated,
edema was prominent, and reactive astrogliosis occurred. When siAQP4 was
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administered after jTBI, there was functional improvement, decreased edema, and
decreased reactive astrogliosis. When siCx43 was administered, there was functional
improvement and decreased reactive astrogliosis, but the level of edema did not change.
From these findings, it can be seen that (1) AQP4 and Cx43 are upregulated acutely after
jTBI, (2) both siAQP4 and siCx43 have therapeutic potentials after jTBI leading to
functional recovery, (3) although both target astrocyte endfeet proteins, the mechanism of
action seem to be different and AQP4 may play a more direct role in the edema process
than Cx43.
Future studies could focus on (1) a more clinically relevant delivery of siRNA for
jTBI, (2) elucidating the mechanism behind functional improvement of siCx43, and (3)
the relationship between AQP4 and Cx43 regarding astrocyte pathology after jTBI.

xv

CHAPTER ONE
INTRODUCTION

Clinical Relevance of Juvenile Traumatic
Brain Injury
Traumatic brain injury affects at least 1.7 million people in the U.S. directly; and
this number does not include patients in military, federal, or veterans affair hospitals, or
people who are not medically treated (Faul et al., 2010). TBI contributes to 30.5% of all
injury related deaths in the U.S. and causes a huge financial burden. Of especially great
concern is juvenile traumatic brain injury (jTBI), which is the major cause of death and
disability in children and adolescents, causing about half a million to get emergency care,
and the number is still growing (Faul et al., 2010). jTBI causes long lasting debilities that
can affect the children’s physical, mental, and emotional ability well into adulthood.
Despite the damages jTBI cause at the individual, communal, and national level, no
effective pharmacological treatment exists to date.
One can say that TBI causes an onset of two stages of injury: primary and
secondary. Primary injuries are the initial damages resulting from a direct and immediate
mechanical disruption of the brain tissue and leads to secondary injuries, which are
indirect and more delayed mechanisms. The severity of primary injuries have been
decreased in recent years due to increased public and legislative awareness concerning
preventive measures such as wearing helmets when engaging in a potential TBI causing
event such as riding bicycles. Thus, research in the development of efficient post-injury
therapeutic treatments should focus on targeting secondary injuries (Morales et al., 2005).
1

In order to accomplish this, a better understanding of the pathophysiological molecular
changes that occur in the brain at later time points post injury is needed. This knowledge
of the long term alterations post-injury is critical in jTBI because the brain is still
developing, and secondary injuries may have a more severe and long lasting effect in the
child’s cognitive, emotional, and motor functions than in adult. One such key secondary
pathological hallmark responsible for the deaths and disabilities after jTBI is cerebral
edema (Huh and Raghupathi, 2009).

Cerebral Edema
Edema is an abnormal accumulation of water, whether inside the cell or in the
extracellular space. Traditionally, cerebral edema has been categorized into two general
types: cytotoxic and vasogenic (Klatzo, 1967). Cytotoxic edema refers to the cellular
swelling due to water moving from the extracellular space into the intracellular space
without disruption of the blood brain barrier (BBB), and vasogenic edema refers to the
accumulation of water from the blood to the brain parenchyma, due to the disruption of
the BBB (Papadopoulos and Verkman, 2007). However, recent findings have led some to
suspect cerebral edema to be a more complicated process with further stages of
characterization (Simard et al., 2007; Unterberg et al., 2004). One example of this is a
further categorization of cerebral edema into three stages: anoxic edema, ionic edema,
and vasogenic edema (Badaut et al., 2011b), taking into consideration the recent
knowledge on molecular and cellular mechanisms involved in edema formation. Anoxic
edema occurs within minutes after the cessation of oxygen and energy (such as glucose)
supplies that result in ionic gradient abnormality, finally causing astrocytic swelling as
described for cytotoxic edema. In a continuous gradient, the endothelial cells suffer from
2

the energy depletion, which contributes to ionic pump dysfunction which results in water
flow into the brain extracellular space before physical disruption of BBB. This phase is
called ionic edema that further exacerbates astrocyte swelling and neuronal cell death.
The final stage termed vasogenic edema occurs because of a massive disruption of BBB
due to endothelial tight junction destruction, causing leakage of plasma proteins into the
brain parenchyma, with water following. Regarding TBI, during anoxic and ionic edema,
cellular swelling and the resultant damage most likely spreads from the initial impact site
to regions further away, affecting more distant cells due to the characteristic network
organization of astrocytes, connected by gap junctions. As such, edema most likely
involves several proteins in the astrocyte, especially those expressed in the perivascular
astrocyte and astrocyte-astrocyte junctions. Thus, we believe that reducing edema
formation by targeting these key components of the edema process is an effective
strategy to facilitate recovery or reduce the secondary damages caused after jTBI.

Aquaporin 4, a Key Astrocyte Water Channel Protein is
Responsible for Edema Formation
Aquaporin is a family of water channel protein that is expressed in most
organisms, including rodents and humans. To date 13 AQPs have been identified in
mammals, and 3 AQPs in the brain have been characterized so far: AQP1, AQP4, and
AQP9 (Badaut et al., 2011b). The aquaporin family exhibits a common structure with six
membrane spanning alpha helical domains, a consensus motif composed of AsparagineProline-Alanine (NPA) constituting part of the pore, and an approximate molecular
weight of 30 kDa (Gonen and Walz, 2006). AQP4 is the most abundant AQP found in the
primate and rodent brains, mainly in the perivascular astrocyte endfeet (Badaut et al.,
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2002). AQP4 is assembled in homo-tetramers where each individual aquaporin represents
a water channel (Yu et al., 2006). The assemblage of four molecules of AQP4 forms a
central pore, through which water, cations, and gases such as CO2 flow (Musa-Aziz et
al., 2009). The main function of AQP4 is widely accepted as facilitating water mobility
(Badaut et al., 2011b), and thus have been studied in relationship with the edema process
(Fukuda and Badaut, 2012). Recently, this was observed using in vivo inhibition of
expression of AQP4 with specific siRNA targeting AQP4 (Badaut et al., 2011a), and
using diffusion weighted magnetic resonance imaging (DWI), which is widely accepted
as a measure of water mobility (Badaut et al., 2011a).

Connexin 43, a Key Protein Forming the Astrocyte Network may
be Responsible for Edema Spread
In the brain, not only neurons, but also astrocytes form a network in which
individual astrocytes connect with each other, exchange information, and influence each
other and the network as a whole. Appropriately, the term astrocyte network (Giaume et
al., 2010) is frequently used to describe this characteristic. In the network, astrocytes are
interconnected with each other through gap junctions, which are made of connexin
proteins: predominantly connexin 43 (Cx43), but also connexin 30 (Cx30), that facilitate
intercellular communication, and possibly intracellular communication (Wolff et al.,
1998). The connexin subtypes are named according to their molecular weight, thus Cx43
has a molecular weight of 43kDa and Cx30 has that of 30kDa. Six connexin proteins
form a connexon, which is a hemichannel, and when a hemichannel from one cell is
aligned with another hemichannel of an adjacent cell, that is called a gap junction.
Therefore, 12 connexins make up one gap junction. Of these connexins, Cx43, which is
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predominantly astrocytic (Giaume et al., 2010; Rash et al., 2001), is one of the most
studied connexin in the brain and highly expressed because astrocytes far outnumber
other cell types in the brain, including neurons (Sofroniew and Vinters, 2010). Connexin
43 form a hemichannel, which form a gap junction, which has an aqueous pore and
selectively permits flow of small endogenous molecules such as second messengers,
amino acids, nucleotides, small peptides, and also water intercellularly between
astrocytes (Giaume et al., 2010; Goodenough and Paul, 2003; Herve and Derangeon,
2012; Wallraff et al., 2006). Although various cell types such as neurons,
oligodendrocytes, and endothelial cells swell after injury, astrocytes are the first cell
types to swell, and the swelling lasts the longest; in fact, perivascular astrocyte endfeet
can swell within minutes after injury (Grange-Messent and Bouchaud, 1994), and this
swelling may spread from primary injury site to distant sites because of the astrocyte
network mediated by gap junctions. This hypothesized spread of detrimental factors from
the primary injury site to more distant sites mediated by gap junctions is often referred to
as “bystander effect” (Andrade-Rozental et al., 2000; Cronin et al., 2008; Perez
Velazquez et al., 2003). Thus, the inhibition of connexin 43 will decrease this bystander
effect and lead to better recovery after jTBI. Accordingly, several studies have shown
that administering gap junction inhibitors such as carbenoxolone and octanol after brain
pathology resulted in beneficial outcome (Andersson et al., 2011; Frantseva et al., 2002;
Perez Velazquez et al., 2006; Rawanduzy et al., 1997) . However, gap junction inhibitors
are not specific for individual connexins or particular cell types and have side effects,
thus unable to pinpoint the function of each connexins in a definitive manner, and
difficult to transition as a clinical therapeutic (Goodenough and Paul, 2003). Furthermore,
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recent studies have shown that non gap junction forming hemichannels may have specific
functions as well such as extracellular signaling of ATP and glutamate under
physiological and pathological conditions (Kar et al., 2012). Therefore, the usage of
specific connexin inhibitors will be of paramount importance not only in learning about
the physiological functions under normal and pathological conditions, but also as
potential therapeutics.

T2 Weighted Imaging and Diffusion Weighted Imaging in the
Assessment of Edema
Clinically, Diffusion Weighted Imaging (DWI) alongside the standard T2
weighted imaging (T2WI) is used widely as a diagnostic tool in clinical and research
settings; among them to assess edematous damage after various brain pathologies from
ischemic stroke to TBI (Chastain et al., 2009; Obenaus and Ashwal, 2008; Tourdias et al.,
2009; Tourdias et al., 2011). The computed T2 value is believed to represent the water
content within brain tissues; where increased T2 values correspond to water accumulation
in pathological conditions (Obenaus and Ashwal, 2008).
DWI makes use of the characteristic property of water motion when excited by
magnetic field gradients, and the rate of diffusion of water can be assessed (Bydder et al.,
2001). The rate of diffusion of water is most often interpreted in a value termed the
apparent diffusion coefficient (ADC). The first published data for DWI usage in the
pediatric population was published in 1991 (Rutherford et al., 1991; Sakuma et al., 1991)
and is now quite routinely used in pediatric neuropathologies including jTBI (Badaut et
al., 2007; Galloway et al., 2008; Hou et al., 2007; Utsunomiya, 2011). In animal studies,
DWI has also started to gain popularity (Badaut et al., 2007; Badaut et al., 2011a;
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Bertolizio et al., 2011; Obenaus and Ashwal, 2008; Wang et al., 2007), although there are
many more studies done in adults than juvenile animals. Because there are differences in
brain structure and physiology between the pediatric population and adult population
such as higher water content in pediatric brain, adult TBI studies should not be directly
translated into the pediatric population without careful research and clinical evidence.
Despite the usage of DWI, the exact molecular mechanisms that contribute to
ADC differences are still unknown. But we hypothesize that aquaporin 4 (AQP4), which
has been proposed as a key player in the cerebral edema process in several brain
disorders including TBI, contributes to ADC values. Because DWI detects changes
observed via the excitation of protons, and water molecules are the main source of
protons being detected in the brain, the presence of the water channel protein, AQP4, in
astrocytes suggests a possible involvement. A decrease in the ADC is classically
associated with a decrease in the extracellular space during cellular swelling after brain
injury (Obenaus and Ashwal, 2008). More recently, ADC changes have been
hypothesized to be linked with the level of expression of AQP4. Several experiments
have shown increases in AQP4 expression and increased ADC (Tourdias et al., 2009) and
decreased AQP4 expression with decreased ADC (Badaut et al., 2011a; Meng et al.,
2004). Of note, Tourdias et al. (Tourdias et al., 2011) have shown in a model of acute
brain pathology that AQP4 upregulation was associated with early edema formation via
increased ADC and BBB disruption. With our hypothesized role of Cx43 in edema
spread, we also propose that Cx43, in conjunction with AQP4 will affect ADC values.

7

Evidences Linking AQP4 and Cx43
So far, we have covered how AQP4 and Cx43 can play major roles in the edema
process after jTBI independently. However, in order to maintain homeostasis, astrocyte
proteins have to work in an intricate concerted manner. Is there a possibility that AQP4
and Cx43 have regulatory functions on each other? Interestingly, a decrease in Cx43
protein expression and a concomitant decrease in gap junction function after
administration of siRNA against AQP4 in primary astrocyte culture have been reported
(Nicchia et al., 2005). Additionally, brain cell cultures taken from AQP4 -/- mice have
also shown lower Cx43 protein level compared to wildtype (Kong et al., 2008). And also,
transgenic mice lacking Cx43 and Cx30 have decreased AQP4 levels (Ezan et al., 2012).

Small Interference RNA as a Research and Therapeutic Tool to
Downregulate AQP4 and Cx43
In order to test our hypothesis that AQP4 and Cx43 played key regulatory roles in the
post traumatic edema process, we needed to find a tool to specifically downregulate these
astrocyte proteins post-injury. A recently discovered tool that fit this criterion was the
small interference RNA molecules.
Small interference RNA (siRNA) is a short double-stranded molecule composed of
about 20 nucleotide base pairs organized in corresponding sense and antisense strands.
These short double-stranded molecules are produced as a result of an enzyme called
Dicer (Bernstein et al., 2001; Ketting et al., 2001), which cleaves a longer doublestranded RNA present in the cell cytoplasm. These double-stranded RNA composed of
both the sense and antisense strand is a necessary trigger for the generation of siRNA.
This was elegantly demonstrated by Mello and Fire, when phenotypic changes were
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observed in C. elegans following insertion of both the sense and antisense mRNA of a
particular protein, but no changes occurred upon delivery of a single strand of either the
sense or antisense strand (Fire et al., 1998; Montgomery et al., 1998). Once siRNA is
made, it enters a protein complex called the RNA induced silencing complex (RISC)
where Argonaut 2 cleaves the sense strand away from the antisense strand. The antisense
strand remaining within RISC is now free to target complementary endogenous mRNA
for subsequent cleavage by the RISC-Argonaut2-siRNA complex, thereby interfering
with the translation process of that specific protein (Ketting et al., 2001). This ultimately
leads to significant down-regulation of the protein normally encoded by the targeted
mRNA (Figure 1).

9

Figure 1. Basic molecular mechanism of siRNA. 1) The enzyme, dicer, cleaves a double
stranded RNA in the cell cytoplasm. 2) This cleavage forms a shorter double-stranded
RNA composed of both the sense and antisense strand. 3) Once siRNA is made, it enters
a protein complex called the RNA induced silencing complex (RISC) where 4) Argonaut
2 cleaves the sense strand away from the antisense strand. 5) The antisense strand
remaining within RISC is now free to target complementary endogenous mRNA for
subsequent cleavage by the RISC-Argonaut2-siRNA complex, 6) thereby interfering with
the translation process of that specific protein.
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This elegant yet simple mechanism allowed the advent of numerous basic science
discoveries and research advances due to the specificity and potency of the RNA
interference mechanism in targeting proteins of interests. Ongoing research interests
include translational approaches of this newfound mechanism into clinical practice, and using
siRNA as a therapeutic agent against diseases including acute brain injuries (Fukuda and
Badaut, 2013).
Small interfering RNA (siRNA) transfection offers a new exciting therapeutic
possibility for brain disorders, through specific inhibition of translation of one targeted
protein. siAQP4 injection in non-injured rat brains resulted in a significant decrease of
water movement evaluated with magnetic resonance imaging (MRI) and the apparent
diffusion coefficient (ADC) values (Badaut et al., 2011a). Importantly, in vivo siAQP4
injection did not produce adverse side effects or mortalities compared to naïve animals,
suggesting the safety of this method for early inhibition of AQP4 expression after brain
injury (Badaut et al., 2011a). Small interference RNA targeting AQP4 (siAQP4) and
Cx43 (siCx43) are expected to decrease edema formation and improve outcomes after
jTBI. Thus, the dissertation research’s unique purpose is to determine the contribution of
the astrocyte network in jTBI pathophysiology.
Previous experiments have shown that siAQP4 injection in non-injured juvenile
rat brains induced a 50% decrease in water mobility as interpreted from MRI ADC
values, along with a 30% reduction in AQP4 protein expression (Badaut et al., 2011a).
These discrepancies between the two percentage values suggest the possible involvement
of additional molecular players such as Cx43 as proposed above.
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Summary
In summary, jTBI is a serious health concern with no therapeutic treatment
available. Edema, which can be visualized by the usage of DWI, is an effective target to
ameliorate secondary damage caused by jTBI, facilitating improved recovery. In order to
accomplish this, the inhibition of the gap junction protein, Cx43, and the perivascular
astrocyte endfeet water channel protein, AQP4, will be very effective.

Study Objectives
Using AQP4 and Cx43 as siRNA targets provides a unique platform to study the
role of the astrocyte network in water diffusion contributing to edema formation after
juvenile traumatic brain injury.
We will have three different aims split up into three chapters (Ch. 2-4) to answer
our question proposed above. Aim 1 (Ch. 2) will characterize the expression of the
aquaporins after our juvenile traumatic brain injury (jTBI) model, correlating these
protein levels with edema. Aim 2 (Ch. 3) will explore novel therapeutic administration of
siAQP4 in vivo after jTBI with measures on edema formation via MRI, behavior
outcome, AQP4 expressions and histology of the neurovascular unit. Aim 3 (Ch. 4) is to
characterize the expression of the connexins after our juvenile traumatic brain injury
(jTBI) model and explore novel therapeutic administration of siCx43 in vivo after jTBI
with measures on edema formation via MRI, behavior outcome, and Cx and GFAP
expressions.
Together, these novel studies will provide new information and knowledge on
astrocyte pathophysiology and contribute to the development of new therapeutic
approaches for jTBI and other brain injuries associated with the edema process.
12

Key Novelties of the Studies
Characterization of Aquaporin and
Connexin after jTBI
Our study will be looking at the changes in the expression pattern of water
channels and gap junctions after jTBI. Characterization of these proteins has not been
performed in models of jTBI. We will be looking at the spatial and temporal changes of
these proteins along the process of edema formation and resolution. Of particular
importance to our astrocyte network hypothesis, the key astrocyte aquaporin-AQP4 and
connexin-Cx43 will be our central focus in our characterization.

Usage of siRNA against AQP4 or Cx43
In Vivo in the Brain after jTBI
Small interference RNA has been gaining considerable attention and is used as
both a molecular tool and a potential therapeutic agent. However, very few studies use
siRNA in vivo in the brain under pathological and non-pathological conditions. This
study will be the first to use siAQP4 and siCx43 in vivo after jTBI as a therapeutic agent.

Astrocyte Network as a Target to Decrease Edema
We will be the first to target key proteins of the astrocyte network as therapeutic
targets after jTBI. Little is known regarding the changes in astrocyte fates after brain
injuries and the contribution of the astrocyte network in edema formation and resolution.
We hypothesize that the inhibition of AQP4 or Cx43 will result in edema decrease and
better behavioral recovery after jTBI.
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Abstract
Traumatic brain injury (TBI) is one of the leading causes of death and disability in
children and adolescents. The neuropathological sequelae that result from TBI are a
complex cascade of events including edema formation, which occurs more frequently in
the pediatric than the adult population. This developmental difference in the response to
injury may be related to higher water content in the young brain and also to molecular
mechanisms regulating water homeostasis. Aquaporins (AQPs) provide a unique
opportunity to examine the mechanisms underlying water mobility, which remain poorly
understood in the juvenile post-traumatic edema process. We examined the
spatiotemporal expression pattern of principal brain AQPs (AQP1, 4, and 9) after juvenile
TBI (jTBI) related to edema formation and resolution observed using magnetic resonance
imaging (MRI).
Using a controlled cortical impact in post-natal 17 day-old rats as a model of
jTBI, neuroimaging analysis showed a global decrease in water mobility (apparent
diffusion coefficient, ADC) and an increase in edema (T2-values) at 1 day post-injury,
which normalized by 3 days. Immunohistochemical analysis of AQP4 in perivascular
astrocyte endfeet was increased in the lesion at 3 and 7 days post-injury as edema
resolved. In contrast, AQP1 levels distant from the injury site were increased at 7, 30, and
60 days within septal neurons but did not correlate with changes in edema formation.
Group differences were not observed for AQP9. Overall, our observations confirm that
astrocytic AQP4 plays a more central role than AQP1 or AQP9 during the edema process
in the young brain.
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Introduction
Traumatic brain injury (TBI) has been termed a ‘silent epidemic’ in the United States
in recent years because of its increased medical and financial burden. TBI affects about
1.7 million people annually and contributes to 30.5% of all injury-related deaths in the
U.S. An important subgroup of this population are children and adolescents ranging in
age from 0-14 years, of which half a million visit emergency departments for TBI (Faul
M, 2010). Juvenile TBI (jTBI) is the primary cause of death and disability in children and
adolescents (Schneier et al., 2006) with long-term impairments in motor and cognitive
abilities, including deficits in intellectual functioning, attention, memory, language,
sensorimotor, visual-spatial, and executive skills (Adelson and Kochanek, 1998, Adelson
et al., 1998). Despite increases in prevalence and resulting catastrophic effects of jTBI,
there are no effective pharmacological treatments.
TBI in infants and children is more frequently associated with severe brain swelling
than in adults (Lang et al., 1994, Bauer and Fritz, 2004) that may affect the edema
process. Two mechanisms may account for these age-related differences: (i) increased
post-injury cerebral blood flow in the young, and (ii) developmental and mechanical
properties of the brain and skull (Kochanek, 2006). Experimental studies suggest that
post-traumatic edema in the immature brain may also be related to enhanced diffusion of
excitotoxic neurotransmitters, an intensified inflammatory response (Kochanek, 2006),
and higher brain water content in the young rat compared to the adult rat (Dobbing and
Sands, 1981).
Developmental differences in water homeostasis between children and adults may
also account for the observed greater risk of post-traumatic edema in the younger
population. Aquaporins (AQPs), a family of water channel proteins, are recognized to
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have an important role in brain water regulation (Badaut et al., 2011b). In rodents and
humans, AQP4 and AQP1 show increased expression during brain development (Wen et
al., 1999, Gomori et al., 2006, Hsu et al., 2011). To date, three different AQPs (AQP1,
AQP4, and AQP9) have been identified in vivo in the brain and each are hypothesized to
play different roles during normal physiological and neuropathological states (Badaut et
al., 2007). For example, AQP1 in epithelial cells of the choroid plexus appears to
contribute primarily to cerebrospinal fluid formation whereas the neuronal AQP1 may
play a role in pain processing (Oshio et al., 2006). AQP9 in astrocytes and
catecholaminergic neurons may contribute to the regulation of brain energy metabolism
(Badaut, 2010). In contrast, AQP4 appears to have multiple roles including: (i) water
homeostasis and edema formation (Papadopoulos et al., 2004, Badaut et al., 2011a,
Badaut et al., 2011b, Lee et al., 2011); (ii) regulation of synaptic plasticity with
regulation of p75NTR (Skucas et al., 2011); and (iii) modulation of neurogenesis (Zheng
et al., 2010).
The intricate role of brain AQPs after injury may depend on underlying pathology
and type of edema (Badaut et al., 2011b), and AQP findings in several TBI studies using
adult rodents have provided conflicting results. In some reports, AQP4 expression is
increased (Sun et al., 2003, Guo et al., 2006, Ding et al., 2009, Higashida et al., 2011,
Tomura et al., 2011) whereas other investigators have reported decreased expression (Ke
et al., 2001, Kiening et al., 2002, Zhao et al., 2005). Interestingly, more recent studies
have shown both AQP1 (Tran et al., 2010, Oliva et al., 2011) and AQP9 (Ding et al.,
2009, Oliva et al., 2011) increasing after injury. Notably, these previous studies were
undertaken in adult rats and the majority only examined AQP4 expression for up to 48
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hours, without correlations of AQP levels with edema formation and resolution via
neuroimaging. In other injury models, AQP expression is observed acutely and in the
long-term, such as in spinal cord injury where AQP1 (Nesic et al., 2008) and AQP4
(Nesic et al., 2010) are increased 5 and 11 months after injury.
Developmental differences in water homeostasis and AQP expression between
children and adults raises the question whether AQPs play a critical role in regulating
brain water content in the developing brain after TBI. To address this question, we
examined edema formation and resolution using magnetic resonance imaging (MRI) in
conjunction with protein levels of AQP1, 4, and 9 by immunohistochemistry and western
blot in a model of jTBI.

Material and Methods
Animals
All protocols and procedures were in compliance with the U.S. Department of
Health and Human Services Guide and were approved by the Institutional Animal Care
and Use Committee of Loma Linda University. Briefly, juvenile male Sprague-Dawley
rats (P10, Harlan, Indianapolis, IN) were housed with their dams on a 12-hour light-dark
cycle schedule, at constant temperature and humidity, for seven days prior to surgery at
P17. Upon weaning at seven days after surgery, the rats were housed two per cage.
Animals were fed with standard lab chow and water ad libitum.

Juvenile Traumatic Brain Injury Model
Controlled cortical impact (CCI) was induced in 17 day old rat pups as previously
described (Ajao et al., in press). Briefly, P17 juvenile rats were anesthetized with
24

isoflurane (Webster Veterinary Supply, Inc., Sterling, MA) and placed into a stereotaxic
frame (David Kopf Instruments, USA). Following a midline skin incision over the skull,
a 5mm craniotomy was performed over the right frontal-parietal cortex (Bregma: -1mm
anterior-posterior and 2mm medial-lateral). CCI was induced in the jTBI group using a
3mm rounded-tip metal impactor fixed to an electromechanical actuator and centered
over the exposed dura at a 20° angle to the cortical surface (Leica Microsystems
Company, Richmond, IL). The CCI was delivered at a 1.5 mm depth with impact
duration of 200 ms at a velocity of 6 m/s. The surgical site was sutured after recording
any bleeding or herniation of cortical tissues (Ajao et al., in press). After the craniotomy,
the dura was intact in all of the animals in both groups (sham and jTBI). After induction
of jTBI none of the animals had bleeding and all of the animals had a similar minimal
damage on the dura. Body temperature was maintained at 37°C during surgery.
Following surgery, animals received one subcutaneous injection of buprenorphine
(0.01mg/kg; dilution: 0.01mg/ml) for pain relief before the animals were returned to their
cages.

Magnetic Resonance Imaging and Analysis
Magnetic Resonance Imaging (MRI) was performed at 1, 3, 7, and 30 days postinjury (d). Rats were lightly anesthetized using isoflurane (1.0%) and then imaged on a
Bruker Avance 11.7 T MRI (Bruker Biospin, Billerica MA, 8.9 cm bore) for the 1, 3, and
7d timepoints, or on a larger bore (40 cm) 4.7T MRI (Bruker Biospin, Billerca, MA) for
the 30d scan, based on the size of the animals (Badaut et al., 2011a; Ajao et al., in press).
Two imaging data sets were acquired: 1) a 10 echo T2 weighted imaging (T2WI), and 2)
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a diffusion weighted imaging (DWI) sequence where each sequence collected twenty
coronal slices (1 mm thickness and interleaved by 1 mm). The T2 sequence had the
following parameters: TR/TE = 4600 ms/10.2 ms, matrix = 128 X 128, field of view
(FOV) = 3 cm, NEX = 2 and acquisition time = 20 min. The spin echo diffusion sequence
parameters were TR/TE = 3000 ms/25 ms, b-values = 0.72, 1855.64 s/mm2, matrix = 128
X 128, FOV = 3 cm, NEX = 2 and acquisition time = 25 min.
Spin-spin relaxation time (T2) and apparent diffusion coefficient (ADC) values
were quantified using standardized protocols (Badaut et al., 2007). T2 relaxation rates
were determined for each pixel and T2 maps generated. ADC maps were calculated using
a linear two point fit. Four primary regions of interest (ROIs) within ipsi- and
contralateral hemispheres (cortex and striatum) were delineated on T2WI. These ROIs
were overlaid onto corresponding T2 and ADC maps and the mean, standard deviation,
number of pixels, and area for each ROI were extracted. MRI analysis was performed
blinded without knowledge of experimental group. Data were represented as percentage
of sham values to facilitate comparison to AQP changes.

Tissue Processing
Rats were transcardially perfused with 4% paraformaldehyde (PFA) prepared in
phosphate buffered saline (PBS) at 1, 3, 7, 30, and 60 d. Brains were immersed in 30%
sucrose at 4oC for 48 hours and then frozen on dry ice and stored at -20oC (Badaut et al.,
2004). Free-floating coronal sections were cut on a cryostat (Leica CM1850, Leica
Microsystems GmbH, Wetzlar, Germany) at 15µm thickness for 1, 3, 7, and 30 d tissue,
and at 50µm thickness for 60d tissue.
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Immunohistochemistry
All antibody incubations were carried out in PBS (Fisher Scientific, Pittsburgh,
PA) containing 0.25% Triton X-100 and 0.25% bovine serum albumin (BSA) (both from
Sigma-Aldrich Co., St. Louis, MO). Briefly, after washes in PBS, sections were preincubated for 90 minutes in PBS with 1% BSA, and then incubated overnight at 4°C with
the various primary antibodies and their respective dilutions as described in Table 1.
After rinsing, sections were incubated for 90 minutes at room temperature with the
secondary antibodies (Table 1). After subsequent washes in PBS for 3x10min, sections
on glass slides were cover-slipped with anti-fading medium VectaShield containing
DAPI (Vector, Vector laboratories, Burlingame, CA). Negative control staining where
the primary antibody was omitted showed no detectable labelling, and depletion of the
AQP4 antibody by an excess of the specific peptide (Chemicon International, Temecula,
CA) was also carried out and gave negative results as previously observed (Ribeiro Mde
et al., 2006).
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Table 1. Antibodies and dilutions used in this study.
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Immunohistochemistry Analysis
Intensity of the AQP4 immunoreactivity was quantified using the LI-COROdyssey analysis software as previously described (Badaut et al., 2011a). Briefly, the
level of fluorescence was quantified in ROIs similar to that of MRI analysis: ipsilateral
hemisphere (lesion and perilesion) and contralateral hemisphere (cortex and striatum).
Values obtained for the jTBI were also normalized to the sham values of the
corresponding ROIs.
Non-infrared stained tissues were observed under an epifluorescent light
microscope (Olympus, BX41, Center Valley, PA USA) and pictures were obtained using
Fluo-Up (Explora-Nova, La Rochelle, France) and confocal microscope (Zeiss). AQP1
and 4 immunostaining were scored using a relative scale including a combination of the
intensity and pattern of staining. AQP1 was scored in the following brain structures:
choroid plexus, ependymal cells of the lateral and third ventricle, and lateral septal
nucleus (n=5-8 animals/region/timepoint). Scoring was given a value from 0-4 with (0)
no staining seen; (1) faint staining in a few positive cells, (2) bright staining in a small
area, or low intensity staining in a larger area (more positive cells), (3) bright staining in a
larger area, or (4) very intense staining over a large area. AQP4 staining was scored on
the tissue collected at 60d with a scale representing the distribution patterns of the protein
on astrocyte endfeet along brain vessels in the ipsilateral and contralateral sides of the
lesion at multiple coronal bregma levels, from 4.2mm to -5.2mm throughout the
longitudinal brain axis (demonstrated in Figure 5). The regions scored for AQP4 were:
dorsal frontal-parietal cortex and lateral parietal temporal cortex in the sham and jTBI
(n=5-8 animals/region). The AQP4 scale was from 0-4 with (0) no perivascular staining,
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(1) few scattered areas of perivascular staining at moderate brightness, (2) many areas of
perivascular staining at moderate brightness, (3) several high density areas of
perivascular staining at moderate brightness (4) entire region has extensive and very
bright staining of AQP4 on perivascular astrocyte endfeet. No analysed regions received
a score of 0, and category 4 was most often observed in anterior sections far from the
injury site.
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Figure 5. Aquaporin 4 Western Blot Analysis Sham vs jTBI. (A) Western blot of AQP4
at 7d shows two distinct bands of AQP4 at around 30kDa, corresponding to the M1 and
M23 isoforms of AQP4. (B) jTBI shows a significantly higher expression of both M1 and
M23 compared to sham. AQP4-M23 was significantly higher than the M1 in sham.
(AQP4, aquaporin 4; kDa, kilo Dalton; jTBI, juvenile traumatic brain injury; *p<0.05,
**p<0.01).
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AQP4 Western Blot Analysis
After magnetic resonance imaging at 7d, brains from 3 animals per group were
freshly dissected with collection of cortex adjacent to the site of the impact. Tissues were
prepared in RIPA buffer with protease inhibitor cocktail (PIC, Roche, Basel,
Switzerland) and sonicated for 30 seconds. One μg of protein was then subjected to SDS
polyacrylamide gel electrophoresis on a 4-12% gel (Nupage, Invitrogen, Carlsbad, CA).
Proteins were then transferred to a polyvinylidene fluoride membrane (PerkinElmer,
Germany). The blot was incubated with a polyclonal antibody against AQP4 (Millipore,
California, 1:2000) and a monoclonal antibody against tubulin (Sigma, Switzerland,
1:25,000) in Odyssey blocking buffer (LI-COR, Bioscience, Germany) for 2 hrs at room
temperature. After washing in PBS, the filter was incubated with two fluorescencecoupled secondary antibodies (1:10,000, anti-rabbit Alexa-Fluor-680nm, Molecular
Probes, Oregon and anti-mouse infra-red-Dye-800-nm, Roche, Germany) for 2 hours at
room temperature. After washing in PBS, the degree of fluorescence was measured using
an infra-red scanner (Odyssey, LI-COR, Germany).

Statistical Analysis
For MRI, infrared ROI, and western blot analysis, a student’s t-test was
performed between groups. Categorical data were assessed using a non-parametric MannWhitney U (M-W) test to assess group differences.
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Results
Apparent Diffusion Coefficient (ADC)
and T2 Values
To address the time course of edema following TBI in our juvenile rat model,
ADC and T2 values were analysed in the ipsilateral cortex including the lesion and the
perilesion regions. Analysis was also performed distant from the injury site, for the
contralateral cortex, ipsilateral striatum and contralateral striatum (Fig. 1). ADC and T2
values were reported relative to sham values. At 1d, ADC was significantly decreased
within the lesion (39.5 ± 2.4%) and perilesion (45.0 ± 2.7%) regions compared to shams.
A significant decrease in ADC values was also observed in the contralateral cortex (41.1
± 9.4%) and striatum (41.3 ± 9.4%) (Fig 1A, B, C). ADC values normalized at 3 and 7d
in all regions (Figure 1A, B, C). However, ADC became significantly elevated in the
jTBI animals at 30 d within the lesion.
Parallel to the ADC changes, T2 values were significantly higher in the jTBI
animals compared to shams at 1d (44.4 ± 3.3% increase in the lesion, 47.5 ± 6.9% in the
perilesion, 46.1 ± 1.6% in contralateral cortex and 46.3 ± 3.5% in the striatum). Edema
remained elevated at 3d for all the regions assessed but returned to sham values at 7 and
30d (Figure 1 D, E, F).
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Figure 1. Changes in T2 and ADC in Sham vs jTBI. (A) DWI at 24hours after jTBI
shows an increase in the size of the lesion and the perilesion compared to the sham group
(B, C) Relative changes of the ADC values in the lesion and perilesion regions (B) and
contralateral cortex (contra-cx) and contra-striatum show a decrease in the ADC values in
all ROIs at 1d then increase at 30d in the lesion (*p<0.01). (D) T2 weighted images (T2)
at 24h after jTBI show the increase of T2 signal in different brain regions compared to
the sham. (E, F) Relative changes of the T2 values in the lesion and perilesion (B) and
contralateral cortex (contra-cx) and contra-striatum show an increase of the T2 values in
all ROIs at 1and 3d before to be normalized in all ROIs. (DWI, diffusion weighted
images; jTBI, juvenile traumatic brain injury; ADC, apparent diffusion coefficient; ROI,
region of interest; d, days post injury; *p<0.01).
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Increase of AQP1 Expression in
Neurons after jTBI
To address the contribution of AQPs following jTBI, we first evaluated AQP1
levels by immunohistochemistry. AQP1 staining was predominantly observed in the
apical membrane of the choroid plexus at similar levels between jTBI and sham groups
(Figure 2 A and B). The absence of differences between groups may be due to the
relatively large distance between the choroid plexus and the site of the impact, which is
approximately 2mm.
A few AQP1 positive neurons were observed in the ipsilateral and contralateral
parietal cortex in sham and jTBI rat pups at each time point as reported previously
(Ribeiro Mde et al., 2006). No overt differences of the AQP1 staining were observed in
the cortical and striatal regions where ADC and T2 values were changed. However, a
striking increase in AQP1 staining was observed in jTBI rat pups after 7d, specifically in
the neuronal dendrites in the dorso-lateral septal nucleus, just below the medial corpus
callosum (Figure 2C-E). While quantification based on the intensity and pattern of the
AQP1 staining at 1 and 3 d showed no significant differences, jTBI animals exhibited a
significant increase at 7, 30, and 60 d (p<0.001) with greater staining intensity on several
neuronal processes compared to sham (Figure 2). The changes in AQP1 expression
starting at 7d strongly suggested that the changes in neuronal AQP1 expression may not
be directly related to edema formation and resolution as observed in MRI.
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Figure 2. Aquaporin 1 Changes Sham vs jTBI. (A) AQP1 staining in the choroid plexus
of sham and (B) jTBI shows no difference in intensity or pattern of staining. (C) AQP1
staining in the dorso-lateral septal nucleus of sham compared to that of (D) jTBI shows a
(E) significant increase in staining in the jTBI animals at 7d, 28d, and 60d.
(AQP1, aquaporin1; jTBI, juvenile traumatic brain injury; DLSN, dorsal lateral sepal
nucleus; d, days post injury; scale bar = 100 μm, *p<0.01).
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AQP4 Expression in Astrocytes
We determined the evolution of AQP4 immunoreactivity (IR) using infra-red
labelling over several post-injury timepoints and compared our results with MRI
detection. Our data indicate several changes over time in the areas ipsilateral to the lesion
(Figure 3) and on the contralateral side (Figure 4). Quantification of AQP4-IR using
infra-red labeling (Figure 3C, 4C) was confirmed at higher magnification with classical
immunostaining (Figure 3B, 4B). The intensity of the AQP4-IR using infra-red labelling
was not significantly changed within the ipsilateral lesion and perilesional cortex between
jTBI and sham animals at 1d (Figure 3). However, AQP4-IR was significantly decreased
in the contralateral striatum in jTBI compared to sham animals, but not in the
contralateral cortex at 1d (Figure 4). When ADC values and T2 values normalized
(Figure 1), AQP4-IR significantly increased within the lesion at 3 and 7d (Figure 3). No
differences were observed in AQP4 staining at 3 and 7 d in the contralateral cortex or
striatum (Figure 4). AQP4-IR normalized at 30 d in all regions (Figure 3C, 4C).
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Figure 3. Aquaporin 4 Changes Ipsilateral Sham vs jTBI. (A) DWI, (A left) and AQP4
immunoreactivity (A, right) at 7d after jTBI show the location of the lesion and perilesion
ROIs used for the analysis and the location of the pictures, B2 and B4 in the red boxes.
(B1, B2, B3, B4) AQP4 (red) and GFAP (green) staining in the lesion area of the
ipsilateral cortex near the surface in cortical layers I-II (B1, B2) and at the layer V (B3,
B4) shows an increase of the AQP4 staining intensity at the glia limitans of jTBI (B2)
compared to the shams (B1) and in the intracortical astrocytes in jTBI (B4) compared to
sham (B3). (Scale bar = 100 μm.). (C) AQP4 staining quantification was performed in the
ROIs (lesion, perilesion, contralaral cortex and striatum, see figure 4). AQP4
immunoreactivity shows a significant increase of the in the lesion and perilesion at 3 and
7d (*p<0.05). (DWI, diffusion weighted imaging; AQP4, aquaporin 4; d, days post
injury; jTBI, juvenile traumatic brain injury; ROIs, regions of interest; GFAP, glial
fibrillary acidic protein).
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Figure 4. Aquaporin 4 Changes Contralateral Sham vs jTBI. (A) DWI (left) and AQP4
immunoreactivity (right) at 1d after jTBI show the location of the contralateral cortex and
striatum ROIs used for the analysis as well as the location of the pictures B2 and B4 in
the red boxes. (B1, B2, B3, B4) AQP4 (red) and GFAP (green) staining in the contracortex (B1, B2) and contra-striatum (B3, B4) show a decrease of the perivascular AQP4
staining in contra-cortex and contra-striatum of jTBI rats (B2, B4) compared to sham
(B1, B3). Scale bar = 100 μm. (C) AQP4 staining quantification shows a significant
decrease of the AQP4 staining in the contra-striatum at 1d (*p<0.05). (DWI, diffusion
weighted imaging; AQP4, aquaporin 4; d, days post injury; jTBI, juvenile traumatic brain
injury; ROIs, regions of interest; GFAP, glial fibrillary acidic protein).
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More specifically, the higher magnification images show decreased AQP4
labeling on the astrocyte endfeet in contact with blood vessels in the contralateral
striatum of jTBI compared to the sham rats at 1d (Figure 4B). At 3 and 7d, the increased
AQP4 IR was not only on astrocyte endfeet but also on astrocyte processes and in the glia
limitans (Figure 3B). The increase in immunoreactivity of AQP4-IR at 7 d was confirmed
by western blot (Figure 5). We observed a significant increase in both isoforms of AQP4
(M23, M1) in jTBI compared to sham animals (Figure 5A). While the ratio of M23 to M1
did not differ between groups, the level of M23 expression was significantly higher than
M1 expression in both sham and jTBI animals (Figure 5B).
At 60d, infra-red analysis showed no overall differences between groups;
however, at higher magnification, AQP4 immunoreactivity revealed differences in the
pattern of the staining (Figure 6). The density and distribution of AQP4 staining was
categorized as Types 0-4 (see Methods and Figure 6C-F). Specifically, jTBI animals
exhibited a scattered pattern of AQP4 immunostaining on the perivascular astrocyte
endfeet in the dorsal parietal cortex region surrounding the lesion cavity at bregma -0.4, 1.4, -2.6 (p<0.05) (Figure 6G) at 60d. No changes were observed between sham and jTBI
groups in the dorsal frontal cortex region at more anterior bregma levels (data not
shown). Notably, the areas of reduced AQP4-staining correspond to the coronal slices
with a visible lesion cavity at 60d. As expected, high AQP4-IR was observed in the glial
scar immediately surrounding the lesional cavity in jTBI animals at 60d (Figure 6B).
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Figure 6. Aquaporin 4 60 days Sham vs jTBI. (A) A mosaic 10X image of representative
Sham with AQP4 in perilesional cortex near Bregma level -2.6mm. (B) A mosaic 10X
image of representative Sham with AQP4 in perilesional cortex near Bregma level 2.6mm. (bars in A, B= 500 μm) (C-F) Representative images from the parietal cortex
showing four immunostaining patterns on astrocyte endfeet resting on micro- and macrovessels. AQP4 was scored according to positive perivascular staining patterns as either
Type 1, Type 2, Type 3, or Type 4. (bars in C-F = 100 μm) (G) Approximated drawing of
the lesion size and location in jTBI animals at 60d (black ovals) located in the
somatosensory cortex and spans a few coronal levels. Categorical AQP4 scores were
assigned to the outlined area at each of the 6 coronal levels depicted. Different staining
pattern of AQP4 protein expression was found in the ipsilateral dorsal cortex of jTBI
nearest to the lesion cavity at Bregma -0.4mm, -1.4mm, -2.6mm, and a trend of smaller
decrease more posteriorly at -3.8mm. (AQP4, aquaporin 4; jTBI, juvenile traumatic brain
injury; d, days post injury; * p<0.05, #p<0.06).
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Taken together, these data suggest that the delayed increase in AQP4 expression
at 7 d is possibly related to the edema resolution (Figure 8) during the first week postinjury. However, by 60d when post-traumatic edema is no longer present, changes in
AQP4 distribution may reflect other pathophysiological changes occurring near the lesion
site and at distance from the impact (Ajao et al., in press).
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Figure 8. Summary Schematic of the Relative Changes in ADC, T2, and AQP4 after
jTBI. Summary Schematic of the Relative Changes in ADC, T2, and AQP4 at the region
encompassing the site of impact: The values are normalized to the sham values, which is
set at 0%. Notice the initial decrease of ADC and increase of T2, accompanied by a
gradual increase in AQP4 values. As AQP4 increases, T2 and ADC start to normalize,
signifying a possible resolution of edema. (AQP4, aquaporin 4; d, days post injury; ADC,
apparent diffusion coefficient).
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Absence of Astrocytic AQP9 Changes after jTBI
Due to the involvement of several AQPs post-injury (Ribeiro Mde et al. 2006), we
also evaluated the pattern of AQP9 in our model. AQP9 staining was observed in
astrocytes of the corpus callosum (CC) and other white matter tracts such as the lateral
olfactory tract (LOT) (Figure 7), in the astrocytes of the subfornical organs, tanycytes and
ependymal cells as previously reported (Badaut et al., 2004). No significant differences in
AQP9 staining were observed between the sham and jTBI animals at any time points.
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Figure 7. Aquaporin 9 Sham vs jTBI. AQP9 showed no significant differences in
intensity of staining or pattern of staining between sham and jTBI at any of the studied
time points. (A1-A4) AQP9 staining of sham colocalized with DAPI and GFAP in the
lateral olfactory tract. (B1-B4) AQP9 staining of jTBI colocalized with DAPI and GFAP
in the lateral olfactory tract. (C1-C4) AQP9 staining of sham colocalized with DAPI and
GFAP in the corpus callosum. (D1-D4) AQP9 staining of jTBI colocalized with DAPi
and GFAP in the corpus callosum. (AQP9, aquaporin 9; GFAP, glial acidic fibrillary
protein; jTBI, juvenile traumatic brain injury; LOT, lateral olfactory tract; CC, corpus
callosum; scale bar = 100 μm).

45

Discussion
Our data suggest that AQP4 plays a significant and more important role than
AQP1 and AQP9 in regulating edema in the immature brain during the first week after
jTBI. Similar to clinical observations, we observed a diffuse increase of brain water
content and decrease of water mobility from regions close to, and far from, the lesion site
in both hemispheres at 1 and 3d post-injury. By 7d, MRI values normalized in parallel
with increases in AQP4 immunoreactivity, a pattern similar to stroke models (Ribeiro
Mde et al., 2006, Badaut et al., 2007). At a distance from the lesion and primary sites of
edema, we observed consistently higher AQP1 staining at 7, 30, and 60 d in neuronal
filaments in the dorsolateral septum, thus highlighting the functional consequences of
neuronal AQP1.
Clinically, diffusion weighted imaging (DWI) and T2 weighted imaging (T2WI)
are useful modalities in the assessment of injury severity and outcome, particularly for
edema formation and resolution (Obenaus and Ashwal, 2008, Chastain et al., 2009,
Badaut et al., 2011b). At 1d, we observed bilateral increases in water content (higher T2)
and decreases in water mobility, as shown by lower ADC values (Figure. 1). It is known
that widespread edema at sites distant from the original impact are more common in
juvenile than adult patients. These changes may be associated with differential
susceptibility to blood-brain barrier (BBB) breakdown and cellular swelling following
TBI (Pop and Badaut, 2011). Later, our ADC values returned to sham values by 3d but
then increased by 30d, while T2 values normalized by 7d and remained stable. However,
the pattern of acute ADC changes described in our study was not observed in a
previously published paper using a rat jTBI model (Bertolizio et al., 2011). This
discrepancy could be due to a difference in the magnet used for the MRI (11.7 T in our
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study vs 4.7T) and also to the definition of the ROI used for analysis (Bertolizio et al.,
2011). In fact, few publications address both ADC and T2 changes in rodent jTBI.
Comparable ADC and T2 changes to our animals were described in focal (Badaut et al.,
2007) and global (Meng et al., 2004) rat pup models of hypoxia-ischemia. Overall, the
patterns in our ADC and T2 data suggest that edema formation in the immature brain
may have cytotoxic and vasogenic components at different post-injury timepoints.
AQPs have been proposed to account for MRI changes reflecting edema
formation/resolution in several rodent models of brain injury (Meng et al., 2004, Tourdias
et al., 2009, Badaut et al., 2011a, Badaut et al., 2011b, Tourdias et al., 2011). Here, we
provided an extensive evaluation of several AQPs at multiple timepoints after jTBI, to
address distinctive profiles during the post-traumatic period in the immature brain. At 1d,
we observed stable levels of AQP4 near the lesion and decreased AQP4 in the
contralateral striatum, in spite of MRI changes occurring bilaterally throughout the brain
hemispheres. One explanation may be that stable AQP4 levels adjacent to the site of
impact may contribute to water entry leading to cellular swelling (lower ADC) and
increased edema (increased T2). At a distance, ADC changes may reflect cellular
swelling secondary to reduced AQP4 (Figure 4), associated with transient water
accumulation. Other models of normal or pathological brain show concomitant decreases
in AQP4 expression and ADC (Meng et al., 2004, Badaut et al., 2011a), or increased
AQP4 and ADC in hydrocephalus and inflammation models (Tourdias et al., 2009).
Notably, a 30% decrease in AQP4 expression using small interference RNA led to a 50%
decrease in ADC values in normal rats (Badaut et al., 2011a). However, in neonatal
stroke models (Badaut et al., 2007) and neuroinflammation in adult rats (Tourdias et al.,
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2011), decreased ADCs did not correlate with AQP4 at 1d, similar to the discrepancies in
our model. These global changes and heterogeneity of AQP4 expression underlie the
complexity of molecular changes behind the fluctuations in water content and mobility
during the edema process after jTBI.
Evidently, AQP4 may not be solely responsible for changes in water mobility
associated with edema development after jTBI, suggesting the participation of other
channel proteins. Two likely candidates are the gap junction protein Connexin-43 (Cx43)
and inwardly rectifying potassium channel 4.1 (Kir4.1). Cx43 is down-regulated after
silencing RNA against AQP4 in primary astrocyte cultures (Nicchia et al., 2005), while
Kir4.1 co-localizes with AQP4 in astrocytic endfeet (Nagelhus et al., 2004). In addition,
cellular potassium reuptake is impaired in an AQP4 knock-out epilepsy model (Binder et
al., 2006) and potassium has been linked with water flux during astrocytic swelling
(Dibaj et al., 2007). It is possible that AQP4, Cx43, and Kir 4.1 may be working in
concert to address brain edema following jTBI.
Edema is a complex molecular process as shown in previous studies examining
post-TBI AQP expression in adult TBI models. Reports of increased AQP4 (Sun et al.,
2003, Guo et al., 2006, Ding et al., 2009, Higashida et al., 2011, Tomura et al., 2011)
versus decreased AQP4 (Ke et al., 2001, Kiening et al., 2002, Zhao et al., 2005) are likely
due to differences in injury type, rodent strains, and age at impact. We expect our
juvenile cortical impact in P17 rats to differ from observations in adult animals,
especially as early brain trauma may interfere with developmental phases and the
evolution and mechanisms of injury. We observed increases in AQP4 at 3 and 7d near the
lesion site in perivascular astrocyte endfeet, astrocyte processes, and the glia limitans.
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These changes may indicate that excess AQP4 could facilitate edematous fluid
elimination through the subarachnoid space (Papadopoulos and Verkman, 2007, Tait et
al., 2010, Tourdias et al., 2011). For example, increased AQP4 in the glia limitans may
compensate for water accumulation at 1 and 3d (higher T2), with a gradual increase of
AQP4 at 3d and normalization of both AQP and T2 values by 7d. This increase of AQP4
at 3 and 7d also parallels the restoration of the BBB with decreased IgG extravasation at
3d and no disruption by 7d (Pop and Badaut, 2011). Although AQP4 improves water
removal, it can also regulate the initial formation of edema (based on increased T2 values
at 1d) as previously proposed (Papadopoulos and Verkman, 2007, Tait et al., 2010).
Thus, inhibiting AQP4 immediately after juvenile injury could be beneficial for edema
reduction as shown in several other injury models (Manley et al., 2000, Papadopoulos
and Verkman, 2005, Saadoun et al., 2008, Badaut et al., 2011b, Higashida et al., 2011,
Igarashi et al., 2011).
Disproportionate levels of AQP4 isoforms and their ratios may interfere with the
protein’s function, due to incorrect formation of the orthogonal array of particles, as
described in stroke models (Badaut et al., 2011b). Moreover, although there is no general
consensus and it remains controversial in vivo, some data show that the M1 isoform may
have a higher water permeability than the M23 isoform (Fenton et al., 2010). This
difference in water permeability may account for significant increases in the M1 isoform
alone during stroke-related edema (Hirt et al., 2009). In our model, we detected higher
protein levels of both isoforms on the impacted side compared to sham animals (Figure
5), higher levels of M23 than M1 in both groups, and no changes in isoform ratios.
Together, these data suggest that the individual orthogonal array of particle arrangement
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may be similar between sham and jTBI by 7d, when the majority of edema and BBB
disruption processes are nearly resolved.
We provide an evaluation at delayed post-injury timepoints, in contrast to reports
in the adult literature focusing on the acute phase. Although AQP4-IR intensity was
similar at 60d between groups, the pattern of AQP4 staining was different in jTBI
animals. Notably, fewer scattered areas of perivascular AQP4 staining were observed in
the parietal cortex near the lesion site in jTBI compared to sham by 60d. Long-term
changes of AQP4 have been observed in other models such as spinal cord injury (Nesic et
al., 2010), mouse models of Alzheimer disease (Wilcock et al., 2009, Yang et al., 2011),
and Alzheimer disease patients (Wilcock et al., 2009, Moftakhar et al., 2010). These
findings strengthen the concept that AQP4 may have additional roles that are not edemarelated after certain injuries, such as cell migration (Saadoun et al., 2005, Auguste et al.,
2007). In human and rat models of spinal cord injury, the ratio of GFAP to AQP4 in
astrocytes around the lesion depend on both the time after injury as well as the severity of
injury (Nesic et al., 2010). Thus, it is possible that the gliovascular unit as a whole is
chronically affected. Further long-term studies of the gliovascular unit after jTBI should
evaluate phenotypic changes in astrocytic networks in microvascular trees and functional
correlations of those changes.
A few TBI studies describe increases in neuronal AQP1 (Tran et al., 2010, Oliva
et al., 2011) and AQP9 (Ding et al., 2009, Oliva et al., 2011) after injury in adults. In our
jTBI model, AQP1 expression in the choroid plexus did not differ between sham and
jTBI at any time points. However, we found more intense AQP1 staining in neuronal
filaments in the dorsolateral septum in jTBI animals at 7, 30, and 60 d. Neuronal septal
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tracts are involved in a number of cognitive pathways including learning, memory, sexual
behavior, positive reinforcement, and pain (Gallagher et al., 1995, Singewald et al.,
2011). Although consensus has not been established concerning the role of AQP1 in pain
processing (Borsani, 2010), AQP1 knock-out mice had reduced pain responses versus
wild-types (Oshio, 2006). TBI patients also report varying degrees of acute and chronic
pain post-injury (Borsook, 2011; Nampiaparampil, 2008). Thus, septal increases in
AQP1 and their influence on pain processing may be further elucidated in this jTBI
model, by using appropriate nociceptive testing paradigms.
AQPs likely contribute to the evolution of several nervous system disorders, and
can serve as potential therapeutic targets to improve clinical outcomes post-injury. Longterm changes in AQP4 and AQP1 after jTBI highlight differences in the edema process
occurring during a developmental period. Notably, edema can have different timelines for
resolution in the young versus adult brain. Our data also confirm the importance of
optimal timing for the administration of therapeutic agents targeting AQPs. While AQP
therapies have been previously suggested for different pathologies such as stroke (Badaut
et al., 2011b), optimal results can only be achieved when accounting for injury-specific
parameters. It is important to consider age at injury (e.g. adult versus juvenile), type of
injury model (e.g. cortical impact, fluid percussion, weight drop, craniotomy versus
closed-head), and post-injury evaluation timepoints. Finally, no single model (e.g. TBI or
stroke) can define the whole spectrum of a given pathology (e.g. edema) over time.
Therefore, observational studies at multiple timepoints are valuable and necessary to
adequately characterize post-injury sequelae, towards a comprehensive understanding of
differential expression patterns of proteins involved in pathophysiological events. To
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determine the exact contribution of AQP4 on edema formation and resolution in parallel
with our observations, it will be necessary to pursue a more functional study directed
towards blocking or increasing AQP4 expression.
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Abstract
Traumatic brain injury (TBI) is common in young children and adolescents and is
associated with long-term disability and mortality. The neuropathological sequelae that
result from juvenile TBI are a complex cascade of events that include edema formation
and brain swelling. Brain aquaporin 4 plays a key role in edema formation. Thus,
development of novel treatments targeting aquaporin 4 to reduce edema could lessen the
neuropathological sequelae. We hypothesized that inhibiting aquaporin 4 expression by
injection of small interference RNA targeting aquaporin 4 (siAQP4) after juvenile
traumatic brain injury would decrease edema formation, neuroinflammation, neuronal
cell death, and improve neurological outcomes.
siAQP4 or a non-targeted-siRNA (siGLO) was injected lateral to the trauma site
after controlled cortical impact in postnatal day 17 rats. Magnetic resonance imaging,
neurological testing, and immunohistochemistry were performed to assess outcomes.
Pups treated with siAQP4 showed acute (3d post-injury) improvements in motor
function and spatial memory at long-term (60d post-injury) compared to siGLO-treated
animals. These improvements were associated with decreased edema formation,
increased microglial activation, decreased blood-brain barrier disruption, and reduced
astrogliosis and reduced neuronal cell death. The effectiveness of our treatment paradigm
was associated with a 30% decrease in aquaporin 4 expression at the injection site.
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Introduction
Traumatic brain injury (TBI) affects about 1.7 million people annually and
contributes to 30% of all injury-related deaths in the United States. An important subgroup are injured children (ages 0-14) of which a half million require treatment in local
emergency departments.(1) Despite this increasing incidence of juvenile traumatic brain
injury (jTBI), there are currently no effective pharmacological treatments.
TBI is divided into two main types of injuries: primary injuries due to a direct and
immediate mechanical disruption of brain tissue; and secondary injuries, a matrix of
delayed events affecting neuronal, glial, and vascular structures.(2) The severity of
primary injuries has decreased in recent years due to increased public and legislative
awareness concerning preventative measures such as regulation of motor vehicle speed
limits and wearing protective helmets during competitive sport activities. Thus,
development of effective post-injury treatments should focus on targeting secondary
injury cascades. This is especially important in jTBI because the brain is still undergoing
development and secondary injuries are more severe in the pediatric than in adult
population with long lasting cognitive, emotional, and motor effects.(3) Secondary
injuries including blood-brain barrier (BBB) disruption and edema formation are
pathological hallmarks after jTBI and contribute to the myriad of long lasting
consequences of jTBI(4), and make excellent clinical targets for improving outcome. We
recently characterized the behavioral changes, brain tissue properties, as well as
neurovascular unit transformation up to 60 days after a controlled cortical impact in
juvenile rats (post-natal 17 days old) (5-7).
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Aquaporin 4 (AQP4) is mainly expressed in perivascular astrocytic endfeet and is
the most abundant brain aquaporin and has been shown to play a central role in edema
formation in several cerebrovascular diseases.(8) However, the beneficial or deleterious
role of AQP4 in edema formation remains unclear and depends on the pathological
model(9). We recently showed an increase in edema formation at 1 and 3 days postinjury with concomitant decreased apparent diffusion coefficient (ADC) and increased T2
values in a model of jTBI (6). These MRI changes were associated with increase of the
AQP4 expression at 3d, suggesting a central role of AQP4 in edema formation in jTBI
(6). Nonetheless, several studies using AQP4 knockout mice have shown significant
decreases in edema formation in several injury models, including adult TBI.(10) Despite
several recent reports proposing the use of ionic channel inhibitors to block AQP4
channels(11) and pretreatment with certain drugs(12), there are no specific AQP
inhibitors available for clinical use.(8) Recently, small interfering RNA (siRNA) to
transiently knockdown proteins of interest has garnered considerable translational
attention with improvements noted in clinical trials using siRNA against VEGF receptors
for the treatment of cancer (13). In our group, we have recently shown that siRNA
against AQP4 (siAQP4) can effectively reduce brain AQP4 expression in vitro and in
vivo(14). In the present study, we hypothesized that using siAQP4 injection as a
treatment to decrease AQP4 expression after controlled cortical impact (CCI) in juvenile
rats would decrease edema formation, BBB disruption and neuroinflammation
(astrogliosis and microglia activation) as well as improve neurological outcomes.
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Materials and Methods
Animals
Manuscript was written in accordance with the ARRIVE guidelines. Experiments
and care of animals were conducted according to the principles and procedures of the
Guidelines for Care and Use of Experimental Animals and were approved by the Loma
Linda University Institutional Review Board. Sprague Dawley rat pups at postnatal day
17 (P17) were housed in a temperature controlled (22-25oC) animal facility on a 12-hour
light/dark cycle 7 days before the surgery.

siRNA Preparation
An in vivo AQP4 silencing protocol was adapted as described in our previous
studies.(14) Briefly, SMART-pool® containing 4 siRNA-duplexes against AQP4 (400ng,
siAQP4, Dharmacon Research) and non-targeted siRNA (siGLO RISC-free-controlsiRNA, Dharmacon Research) were mixed with interferin® (Polypus-transfection,
Illkirch, France) diluted in a saline solution (0.9%) containing 5% glucose for a final
volume of 5 L and incubated on ice for 20 min before injection.

Controlled Cortical Impact (CCI) Injury
and siRNA Injection
Controlled cortical impact (CCI) was carried out in P17 rat pups as previously
described.(5) Rats were anesthetized with isoflurane (2%) and placed in a stereotaxic
apparatus (David Kopf Instrument, Tujunga, USA) where a 5 mm diameter craniotomy
was performed over the right hemisphere at 3 mm posterior from the bregma and 4 mm
lateral to the midline. Animals were subjected to a CCI with a 2.7 mm round tip angled
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20 degrees at a velocity of 6 m/s to a depth of 1.5 mm below the cortical surface using an
electromagnetic impactor (Leica, Richmond, IL). After craniotomy, the dura was intact in
both groups and after induction of TBI none of the animals in siGLO and siAQP4 groups
had major bleeding or herniation of cortical tissues.
Injection of siRNA was performed 10 min after the injury lateral to the site of the
impact using a 30-gauge needle on a Hamilton syringe (3 mm posterior to bregma, 6 mm
lateral to midline, and 1.0 mm below cortical surface). The syringe was attached to a
nanoinjector (Leica, Richmond, IL) and a volume of 4 L of siRNA was infused at a rate
of 0.4 L/min. After suturing, all pups received an intraperitoneal injection of
buprenorphine (0.01 mg/kg, Tyco Healthcare Group LP, Mansfield, MA) for pain relief
and then placed on a warm heating pad for recovery before being returned to their dams.
A second siRNA injection was repeated 2 days later in all pups using the same injection
protocol. Total number of animals used for the study was 27 rats divided in n=15 rats for
siGLO and n=12 for siAQP4 group.

Magnetic Resonance Imaging (MRI)
MRI was performed at 1 and 3d. Pups were lightly anesthetized using isoflurane
(1.0%) and imaged on a Bruker Avance 11.7 T (Bruker Biospin, Billerica, MA).(15) Two
imaging data sets were acquired: 1) a 10 echo T2- and 2) a diffusion weighted imaging
(DWI) sequence in which each sequence collected 20 coronal slices (1 mm thickness and
interleaved by 1 mm). The 11.7T T2 sequence had the following parameters: TR/TE =
2357.9 / 10.2 ms, matrix = 128 x 128, field of view (FOV) = 2 cm, and 2 averages. The
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DWI sequence had the following parameters: TR/TE = 1096.5 / 50 ms, two b-values
(116.960, 1044.422 s/mm2), matrix = 128 x 128, FOV = 2 cm, and 2 averages.

Region of Interest (ROI) and Volumetric Analysis
T2 and apparent diffusion coefficient (ADC) values were quantified using
previously published standard protocols (14). Regions of interest (ROIs) were placed on
the imaging section with the maximally detected injury using Cheshire (Parexel
International Corp. Waltham, MA). Lesion and ipsilateral hippocampus were delineated
on T2 images and overlaid onto corresponding T2 and ADC maps. The mean, standard
deviation, and area for each ROI were extracted.

Behavioral Testing
The behavioral evaluation was performed on 2 independent sets of animals. Footfault and rotarod testing was performed at 1, 3, 7 and 60 days, where the foot-fault test
evaluated sensorimotor and proprioception while the rotarod test evaluated sensorimotor
coordination as previously reported in our earlier studies.(5) All tests at each time-point
were carried out on siGLO and siAQP4 treated jTBI rats within a 3-hours morning timeblock (8 – 11 am). siGLO and siAQP4 treated jTBI rats were interleaved in testing
sequence. To further control potential confounds, the same tests were administered in the
same order at all of the time points, by the same investigators (AA, VP, JC) blinded to the
experimental groups. For the behavioral tests the videos and the extraction of the data
were carried out by JB and RH, who were also blinded to the experimental groups.
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Foot-fault testing was carried out on an elevated platform (50 cm X 155 cm,
ClosetMaid, Ocala, FL) with parallel wire bars 1.5 cm apart and raised 100 cm above the
floor at 1d, 3d, 7d, and 60d. Rats were placed in the middle of the platform and
movements were video-recorded for a period of 60 sec. in two separate trials, 30 min.
apart. When a rodent’s paw (fore- or hindlimb) slipped completely through the wire
mesh, it was considered as an individual fault. The average foot-fault score was
calculated from the total number of faults from two 60 sec trials.
Rotarod evaluation was performed on all the animals at 1d, 3d, 7d, and 60d (SD
Instruments, San Diego, CA). A rotating 7 cm-wide spindle with a continuous speed (20
RPM) was used to evaluate performance during two trials (15 min apart). Latency to fall
was recorded as a measure of motor coordination and balance. The maximum time spent
on the test was 60s, if the rat did not fall. The two fall latencies were summed and express
in total time (s) for 2 trials.
At 60 days post injury a battery of tests were performed over 4 days to evaluate
the overall cognitive performance of the animals including open field, zero maze, and
Morris Water Maze (MWM) (5). 1) Open field was used to assess the overall locomotor
activity in a plastic box (50 x 36 x 45 cm), and each rat was monitored for 30 min with an
overhead video camera using Noldus Ethovision software (Tacoma, WA). The total
distance traveled by each rat was recorded (5). 2) On day 2, the elevated zero maze tests
used an elevated circular track 10 cm wide with a 100 cm outer diameter and 2 sets of 30
cm high walls enclosing two opposing quadrants of the track, leaving the other two
opposing quadrants open and brightly lit. This test was used to evaluate anxiety-like
behavior by a 5 min observation, and the outcome measure was the percentage of the
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time spent in the enclosed (dark) half of the maze. 3) Finally, the MWM test was carried
out to assess spatial learning and memory in the rats. The test consists of a tank of 100
cm in diameter, filled with opaque water and an 11 cm diameter escape platform was
placed. Recording the animal with an overhead camera and the Noldus Ethovision system
allowed for assessment of variables such as swim distance, swim speed, and relative
angular velocity (left / right turn bias). The first day of testing consisted of the cued
learning paradigm, designed to test for non-associative factors that could affect the
scoring on the MWM, such as motivation, swimming ability, and vision. The platform
was visible by protruding 2 cm above the waterline with a 40 cm wooden rod attached.
Animals were placed in the tank and required to simply swim to the visible platform to
end the task. Each animal completed 10 trials consisting of 5 blocks of 2 trials each, with
their starting location and that of the platform being shifted throughout the task. If the rat
had not found the platform after 60 sec, it was guided to the platform, where it remained
for 5 seconds. The swim path was recorded and each animal’s total swim distance
determined for each trial. The following days 2 and 3 of the MWM consisted of the
spatial paradigm, designed to measure an animal’s ability to learn and remember a hidden
platform’s location in the tank. During this paradigm, the platforms submerged
approximately 2 cm below the water’s surface, and release points varied throughout each
day although the platform remained stationary. As in the cued paradigm, animals were
required to swim to the platform to end the task. Unlike the cued paradigm, hiding the
platform’s surface under the water’s surface required animals to learn and navigate to the
location using spatial cues. Each animal completed 10 trials consisting of 5 blocks of 2
trials each. If the animal had not found the platform after 60 sec, it was guided to and
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placed on the platform, where it remained for 5 seconds. The dependent variable for the
spatial task was cumulative distance to the platform, a variable sensitive to both distance
and time defined as a cumulative total of an animal’s distance from the platform as
measured 5 times every second. After each day of spatial testing, a probe trial was
administered to measure an animal’s ability to remember the platform’s location. This
trial was administered 1 hour after the final spatial trial of the day. The platform was
removed and animals were allowed to search the tank for 60 sec. Dependent variables for
this task included the number of times an animal entered the platform’s previous location
and percent time spent in the target quadrant.

Immunohistochemistry and Image Analysis
At 3d the animals were transcardially perfused with 4% paraformaldehyde, the
brains extracted and put in 30% sucrose for 48 hours and then stored in -22°C. Coronal
sections were cut at 20 μm thickness at -22°C on a cryostat (Leica, Richmond, IL) and
mounted on slides for immunohistochemical analysis (14-16).
For immunoglobulin (IgG) extravasation immunohistochemistry, sections were
washed with PBS, blocked with 1% BSA in PBS, then incubated for 2 hours at room
temperature with IRDye 800 conjugated affinity purified goat-anti-rat IgG (1:500,
Rockland, Gilbertsville, PA) in PBS containing 0.1% Triton X-100 and 1% bovine serum
albumin. After washing, sections were scanned on an infra-red (IR) scanner (Odyssey) to
quantify fluorescence for the different ROIs as previously described.(14) Additional
immunostaining was done for rabbit polyclonal antibodies for AQP4 (1:300, Alpha
Diagnostic, Owings Mill, MD), chicken polyclonal antibodies for glial fibrillary acidic
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protein (GFAP, 1:500, Millipore, Billerica, MA), mouse monoclonal antibodies for
endothelial brain antigen (EBA, 1:1000, Covance, Princeton, NJ), mouse monoclonal
antibodies for Neuronal Nuclei (NeuN, 1:200, Abcam, Cambridge, MA), rabbit
polyclonal antibodies for ionized calcium-binding adapter molecule (Iba-1, 1:300, Wako,
Richmond, VA), and mouse monoclonal antibodies for Claudin-5 (1:200, Invitrogen,
Carlsbad, CA) were used. Sections were washed with PBS, blocked with 1% BSA in
PBS, incubated with the respective primary antibodies overnight, then incubated with
affinity purified secondaries conjugated to the desired wavelength to either be scanned on
an IR scanner or to be observed under a confocal microscope (Olympus). All image
acquisition parameters for the same proteins were kept constant for all of the animals for
analysis and visualization purposes. All analysis was carried out in a non-biased, blinded
manner. AQP4, GFAP, Claudin 5, and Iba-1 were quantified in a similar manner to IgG
extravasation staining as published previously (14). In detail, slides were incubated with
secondaries conjugated to the infrared wavelength of either 680 or 800 nm. These slides
were then scanned on an infrared scanner (Odyssey, Lincoln, NE), where images were
saved with resolution of 21 μm per pixel. Three identical circular regions of interests
(ROIs) were drawn in the perilesional cortex (Fig. 3A) at three different bregma levels (1.40mm, -2.56mm, and -3.80mm): the bregma level where lesion area was largest, one
slice anterior and one posterior, for a total of 9 regions of interests per animal. The
average fluorescence of these regions of interests was calculated. EBA and NeuN
staining was quantified using the Mercator software (Explora-Nova, La Rochelle,
France). The area of EBA staining was measured by drawing an ROI on the acquired
image with the largest legion as determined and confirmed by MRI, and the total area of
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EBA-positive staining was determined and that value was divided by the area of the ROI.
Thus, the % of staining per given area was determined for each animal. NeuN positive
cells were counted on images acquired using constant parameters: i.e. the same values of
the contrast, gain, and brightness were used. Similar to EBA analysis, the tissue section
with the largest legion was selected and the NeuN positive cells were counted in an
automated fashion via the Mercator software and the density was determined. Microglial
activation was quantified by calculating the average form factor (FF= 4π*area/perimeter 2
of each cell) from the Iba-1 positive cells using the image software, MorphoPro (ExploraNova) on images acquired using constant parameters: i.e. the same values of the contrast,
gain, and brightness were used. Negative control staining where the primary antibody or
secondary antibody was omitted showed no detectable labelling.
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Figure 3. siAQP4 treatment decreases Blood-Brain Barrier disruption after jTBI. Drawing
of the region of interests (ROIs) used in the study to quantify protein and histological
changes in correlation with the MRI measurements (A). Representative
photomicrographs of IgG-extravasation immunofluorescence (arrows) in siGLO (B) and
siAQP4 (C) treated rat pups. siAQP4 treated rat pups showed significantly decreased
IgG-extravasation staining adjacent to the lesion site compared to siGLO-treated animals
(*, p<0.05), suggesting that the siAQP4 treatment mitigates BBB disruption (D).
Endothelial Barrier Antigen (EBA) is a marker of intact endothelial cells in rats and
disappears when the endothelial layer is disrupted. The arrows in (E) show blood vessels
(asterisks) devoid of EBA staining in siGLO treated animals. In contrast siAQP4 rat pups
had more EBA-positive staining (arrowheads) in the cortical perilesion tissue (F).
Quantification of the EBA staining showed that the siAQP4 treated rat pups had more
EBA-positive staining (arrowheads), suggesting decreased damaged blood vessels in the
perilesion tissues (*, p<0.05) (G). This result is in accordance with the IgG extravasation
data showing improvement of the BBB after siAQP4 treatment (A-C). Similarly, claudin5 staining, a tight junction protein (in green H, I) showed increased staining in siAPQ4 (I,
arrows) compared to siGLO treated rats (H, arrows) and confirmed in the quantification
of claudin 5 immunoreactivity (*, p<0.05) (G). Increased levels of claudin-5 suggest less
BBB disruption consistent with decreased IgG extravasation and increased EBA staining
after siAQP4 treatment. Taken together, siAQP4 treatment results in less BBB disruption
at day 3 after injury as seen by more tight junction proteins, more intact blood vessels,
and less leakage of IgG from the peripheral blood vessels to brain tissue.
Scale bars in A, B=3mm; D, E=100µm.
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Brain Tissue Processing for Western Blotting
A Protein FFPE extraction kit (Qiagen, Hilden, Germany) was used to process
perfused brain slices for Western blotting as previously published (7). Parietal cortical
tissue around the lesion was excised from three coronal sections at bregma levels -1.40, 2.56 and -3.80mm, that were adjacent to slices of interest used for immunohistochemistry
quantification. Briefly, tissue was homogenized and processed according to kit
instructions, and then samples were assayed for total protein concentration by
bicinchoninic acid assay (BCA, Pierce Biotechnology Inc., Rockford, IL). For gel
electrophoresis, all samples were prepared with loading sample buffer and reducing agent
(Invitrogen, Carlsbad, CA) for a total of 2 µg of rat protein loaded on a 4-12% SDS
polyacrylamide gel (Nupage, Invitrogen, Carlsbad, CA). Proteins were transferred to a
polyvinylidene fluoride membrane (PVDF, PerkinElmer, Germany), blocked for 1 hr in
Odyssey blocking buffer (Li-Cor Bio-Science, Lincoln, NE), and incubated with a rabbit
polyclonal anti-AQP4 (1:3000; Alpha Diagnostic, Owings Mill, MD) and mouse antitubulin (1:10,000; Sigma-Aldrich Co., St. Louis, MO), and these blots were co-incubated
with goat anti-mouse secondary antibody coupled with Alexa-Fluor-800 (1:10,000;
Rockland Immunochemicals, Gilbertsville, PA) and goat anti-rabbit secondary antibody
coupled with Alexa-Fluor-680 (1:10,000; Life Technologies: Molecular Probes, Grand
Island, NY) for 2 hrs at room temperature. After PBS washes, the PVDF membrane was
visualized using the Li-Cor infra-red scanner and fluorescence activity was directly
quantified Odyssey software (Li-Cor, Bioscience).
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Statistics
MRI and behavioral data were analyzed by two-way repeated measures analysis
of variance with a post hoc Bonferroni test. One-way ANOVA was used for
immunohistochemistry and western blot analysis. All data are expressed as the mean ±
SEM.

Results
siAQP4 Treatment Reduces AQP4 Expression Acutely
Injection of siAQP4 induced a 31% decrease (p<0.05) in the level of AQP4
expression at 3d (Fig. 1A, B). In support of the Western blot results, siAQP4 treated rats
showed a 27% decrease in AQP4 staining within the perilesional tissues around the
cavity on the ipsilateral cortex as well as a 33% decrease in the ipsilateral hippocampus
compared to siGLO-treated animals (p<0.05) (Fig 1C-G). This decrease in AQP4 staining
after jTBI was of similar magnitude to that which we previously reported in normal (i.e.
no jTBI) juvenile brain tissues after siAQP4 injection(14). In contrast, Western blot and
immunohistochemistry analysis showed no differences in AQP4 expression between
siGLO and siAQP4 treated animals at 60 days (Fig 6A, B, C). No significant changes
found in the contralateral cortex or hippocampus at 3 and 60 days (data not shown).
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Figure 1. Reduced Expression of AQP4 after siAQP4 injection. AQP4 Western blot from
adjacent PFA fixed sections in siGLO and siAQP4 groups showed a band around 34 kDa,
with a decrease of the intensity in siAQP4 treated group. Tubulin was used to normalize
the loading. The quantification of the intensity of the band showed a significant decrease
of AQP4 (p< 0.05). Representative images of AQP4-immunoreactivity in the cortical
perilesion and hippocampus adjacent to the jTBI cavity (*) in siGLO (C) and siAQP4
treated animals (D) at low magnification. AQP4 staining bordering the cavity is
decreased in the siAQP4 (D) compared to the siGLO treated animals (C) at d3 postinjury. Similarly, the AQP4-immunoreactivity is increased in the ipsilateral hippocampus
of siGLO group (C) compared to siAQP4 treated animals (D). At higher magnification in
perilesional cortex (Cx), AQP4 staining is predominant on astrocyte endfeet in contact
with blood vessels (arrows, as previously described, (16)) in siGLO (E) and siAQP4 (F)
animals, with decreased staining of AQP4 in the siAQP4 group. This suggests that the
siAQP4 treatment after jTBI prevents the increase of AQP4 expression on astrocyte
endfeet. (G) AQP4 immunoreactivity was quantified and confirmed a significant
decrease in AQP4-immunoreactivity in the siAQP4 compared to siGLO treated rats in
both the perilesional cortex and ipsilateral hippocampus (*, p<0.05). Taken together,
after jTBI, siAQP4 injection induced a decrease of AQP4-immunoreactivity acutely.
Abbreviation: Cx, cortex; scale bars C, D = 1mm; E, F=100μm.
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siAQP4 Treatment Reduces Acute Edema Formation
As determined by 1d and 3d MRI, we found decreased T2 (edema) and ADC
(water mobility) values in siAQP4 compared to siGLO-treated pups (Fig 2), strongly
suggesting that siAQP4 reduced edema formation. Whereas T2 values increased in the
lesion/perilesion area of siGLO treated rats they were decreased in siAQP4 pups from 1d
to 3d (22% in the lesion/perilesion and 15% in the ipsilateral hippocampus). ADC values
were also decreased by 21% in the lesion/perilesion at 1d (p <0.005) and by 24% in the
ipsilateral hippocampus at 3d (p < 0.001) in the siAQP4 compared to siGLO-treated rats
(Fig 2). Overall, the data suggest an association between the regions showing reduced
AQP4 staining and reduced edema formation (T2) and improved tissue characteristics
(ADC) (Fig 1 and 2).
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Figure 2. Quantitative neuroimaging of jTBI after siAQP4 treatment reveals decrements
in edema. Representative T2 images at day 3 in siGLO and siAQP4-treated pups show
decreased edema at the lesion site following siAQP4 treatment (arrows) (A). siAQP4
pups had significantly decreased edema (*, p < 0.001) compared to siGLO pups within
the lesion at day 3 (B). There was also a significant decrease in edema after siAQP4
treatment at day 3 within the hippocampus, ventral to the injury (*, p<0.001) (b). Water
mobility (apparent diffusion coefficients, ADC) was reduced in the siAQP4 treated pups
(day 1 after injury, arrows) (C). Quantitative ADC revealed significantly decreased water
mobility in siAQP4 pups in the lesion at 1 day after injury compared to siGLO (*, p <
0.001) (D). siAQP4 pups had significantly decreased ADC in the hippocampus at day 3,
but not at 1 day (*, p < 0.001) (D). After jTBI, siAQP4 injection mitigated the edema
formation associated with a decrease of the AQP4 (Fig 1).

80

Reduced BBB Disruption in siAQP4
Treated Rat Pups
Edema formation (i.e. increased T2 values) also appeared to be associated with
BBB disruption, which improved after siAQP4 treatment. BBB integrity was assessed
with claudin-5 (tight junction protein), endothelial barrier antigen (EBA) and IgG
extravasation staining in the perilesional cortex and ipsi-hippocampus (Fig 3). Less BBB
disruption was also shown through decreased IgG extravasation staining intensity by 30%
around the site of the injury in the siAQP4 group (p<0.05) (Fig 3B, C, D). Associated
with decreased IgG staining, a 31% increase in the area of EBA staining in siAQP4 rats
was observed (Fig 3E, F, G). Similarly, Claudin-5 immunoreactivity was higher in the
siAQP4-treated animals around the cavity (Fig 3H, I, J).

Reduced Astrogliosis, Increased Microglial Activation,
and Increased Neuronal Survival in siAQP4 Treated Rat Pups
The effects of siAQP4 on neuroinflammation were evaluated by measurement of
astrogliosis with GFAP-immunoreactivity (Fig 4) and microglia activation with Iba-1
staining (Fig 4). GFAP staining intensity was decreased by 39% around the cavity and by
26% in the ipsilateral hippocampus of siAQP4-rat pups compared to the siGLO group
(p<0.05, Fig 4). In contrast, we observed an increase in the number of activated
microglial cells, showing amoeboid shapes with less ramifications in the lesion site
characterized by higher calculated form factor (FF) in siAQP4 compared to siGLO
treated rats (Fig 4). This observation was also supported by a higher intensity of Iba-1
staining, a specific marker of microglia, using infrared analysis (Fig 4). No significant
differences were observed in the ipsilateral hippocampus.
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Figure 4. siAQP4 treatment reduces astrogliosis and results in microglial activation
acutely after jTBI. Increased GFAP staining after injury is a marker of reactive astrocytes
and astrogliosis associated with neuroinflammation. Representative images of regional
GFAP-immunoreactivity in the cortical perilesion in the siGLO (A) and siAQP4 treated
animals (B). GFAP staining in the region bordering the cavity (*) is decreased in the
siAPQ4 treated rats compared to the siGLO-treated animals at day 3 post-injury.
Similarly in the hippocampus, the presence of GFAP staining in the reactive astrocytes in
the siGLO treated rats (A) is increased compared to siAQP4 treated animals (B). At
higher magnification, increased GFAP positive cells with swollen cell bodies and
processes in the siGLO group (arrows, C) compared to siAQP4 (D) treated rats were
observed in the perilesional cortex. The infrared intensity of the GFAP immunoreactivity
was quantified and showed a significant decrease of GFAP staining in the siAQP4
compared to siGLO treated rats in both the perilesional cortex and ipsilateral
hippocampus (E) (*, p<0.05). The significant decrease of GFAP in the siAQP4 treated
rats suggests that siAQP4 treatment mitigates astrogliosis and the swelling of the
astrocytes after jTBI. Immunoreactivity of Iba1 (red), a specific marker of microglia,
showed a higher intensity of staining in the siAQP4 group (F) compared to siGLO-treated
rats (G). At higher magnification, Iba1 staining presents different morphological patterns
between the two groups, suggesting that the microglia cells do not have the same level of
activation. In the siGLO group (I) Iba1 positive cells appear more ramified (arrows) and
have less amoeboid-like shapes than microglial cells in siAQP4 treated rats (J, arrows).
The amoeboid-like shapes observed for Iba1 positive cells in the siAQP4-treated group
(J, arrows) are associated with a more activated microglia phenotype. To quantify the
morphological differences, form factor (FF) analysis was performed where a higher FF
correspond to a less ramified and more round cells, suggesting a more activated state for
microglia. FF analysis revealed that siAQP4-treated rats had a significantly higher
average FF compared to siGLO group (K) (*, p<0.01) consistent with a more activated
microglia in siAQP4 animals. Infrared analysis showed higher intensity fluorescence in
the siAQP4 animals compared to siGLO at the lesion site (H) (*, p<0.05).
Scale bars in A, B =1mm; C, D =100µm, F, G, I, J = 20 µm.
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The effects of siAQP4 on neuronal survival was also measured by counting the
number of NeuN positive cells (5, 17). At 3d, NeuN positive cells were higher in the
perilesional cortex adjacent to the cavity (62%) as well as in the ipsilateral hippocampus
(56%) in the siAQP4 compared to siGLO-treated pups at 3d (Fig 5).
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Figure 5. siAQP4 treatment increases neuronal survival at 3d post-injury. NeuN
(Neuronal Nuclei) stained sections show a higher staining in the siAQP4 animals (D, E,
F) than the siGLO (A, B, C) in the cortex (A, B, D, E) and the hippocampus (A, C, D, F)
adjacent to the cavity (*). Neuronal cell counts revealed a significant increase in the
number of NeuN positive cells (# of cell/mm 2) in both the perilesion (arrows A, D) and
hippocampus (arrowheads, A, C, D, F) of siAQP4 animals (G) (*, p<0.05), suggesting
improved neuronal survival after injury in siAQP4 treated rat pups compared to siGLO
group. Scale bar A, D = 1.25mm; B, E = 50 µm; C, F = 20 µm.
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At 60d, there were no differences in AQP4 and GFAP staining (Fig 6A, B, and
C). No changes in microglial activation were observed at 60d (Fig 6D). In contrast there
was a significantly higher number of NeuN positive cells in the CA1 region of the
ipsilateral hippocampus in siAQP4 animals compared to siGLO, however no changes
were observed in the ipsilateral cortex (Fig 6F, G, I).
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Figure 6. siAQP4 treatment increases the neuronal survival in hippocampus at 60d.
At 60d, AQP4 expression did not differ significantly between siAQP4 and siGLO as
quantified via Western Blot (A) (B). AQP4 and GFAP staining did not show overall
obvious visible differences in staining intensity or staining pattern between the groups as
shown in the exemplary confocal picture (C). The arrows represent penetrating arteries
stained in both siGLO and siAQP4 (C). At 60d, there were no visible differences in
microglial staining visualized via Iba-1 immunohistochemistry between the siGLO and
siAQP4 animals (D). Form factor analysis showed no significant differences between the
animals, signifying no differences in microglial activation status (E). In the perilesional
cortex of 60d animals, NeuN cell count showed no significant differences (F) (I).
However, in the perilesional CA1 (arrow), siAQP4 animals had significantly higher
number of NeuN positive cells (G) (*, p<0.05, I). A schematic drawing showing the
regions of interests (in red) used to quantify NeuN numbers are shown (H). Scale bar C,
D=50μm; F, G=100μm.

87

Improved Sensorimotor, Proprioception and
Spatial Memory after siAQP4 Treatment
Concomitant with the observed decrease in edema and histological improvements,
motor functions were improved in siAQP4 treated rats. siAQP4 pups had fewer footfaults at 1 and 3d (respectively 34% and 46%, p < 0.05, Fig 7A). After 7d, there were no
more significant differences in the number of foot faults (Fig. 7A). Similarly, siAQP4
treated rats were able to stay on a rotarod 40% longer than siGLO treated rat pups at 3d
(Fig 7B), that returned to baseline at 7d post injury. Long-term improvements were tested
up to 60 days post injury, with a battery of tests assessing several cognitive repertoires.
The open field test did not show significant difference between the groups in overall
locomotor activity (data not shown) and supported the MWM cued test showing no
differences in the ability to swim (data not shown). Similarly, the zero maze tests did not
show differences between the groups with the same time spent in the “dark” quadrants
(data not shown). During the spatial learning on the day1 of the protocol, both groups
were able to perform the task similarly (Fig 7C). However on the second day of the
MWM protocol, when the platform is moved to a second location, siAQP4 animals spent
more time than the non-treated group in trying to find the new location of the platform on
the first block (Fig 7D). This suggests that siAQP4 animals have a better memory of the
previous platform location and thus spent more time at the previous site (Fig 7E). This
data is also supported by the probe test to assess the spatial memory. The siAQP4 treated
rats spent significantly longer times than the siGLO group in the quadrant that previously
contained the platform (Fig 7F). Improvement in spatial memory at 60d post-injury is
associated with higher CA1 neuronal survival in siAQP4 treated group (Fig 6).

88

89

Figure 7. siAQP4 treatment associated with behavioral improvement at short and longterm after jTBI. siAQP4-treated pups had better functional outcomes as revealed by the
foot-fault test. siAQP4 group had significantly fewer foot faults than siGLO treated
animals at day 1 (34%) and day 3 (46%) after jTBI (*, p < 0.05) (A). siAQP4 animals
also performed significantly better on the rotarod test at day 3 compared to siGLO by
staying on for a significantly longer time before falling (*, p<0.05) (B). After jTBI,
siAQP4 treatment improves the proprioception and sensorimotor outcomes in association
with a better neuronal and a decreased edema formation acutely. In MWM test, the
groups did not show overall significant difference in the rate of spatial learning at day 1
(d1, C) and day 2(d2, D). However, the siAQP4 treated animals exhibited higher
cumulative distance value on the first block on d2 (arrows) compared to the non-treated
group, suggesting a better memory of the platform’s previous location. The video track
(E, dark line) shows that the siAQP4 animals spent more time in the quadrant of
platform’s previous location (location noted by blue dotted circle) than the siGLO rats, in
accordance with a better memory. The actual location of the platform is noted by the red
circle (E) and at the opposite location to the previous one. The probe test confirmed this
hypothesis with a significantly higher time spent in the quadrant where the platform was
located for the siAQP4 treated rats compared to the siGLO animals (F). All these data
showed that siAQP4 treatment improve the short and long-term behavioral outcomes.
In summary (G1 and G2), the primary injury induces a cascade of secondary of injuries
involving AQP4 and water flow in brain tissue, which contributes to the edema formation
(measured with T2 and ADC) and BBB disruption after jTBI. Downstream to these
changes, there is neuroinflammation with astrogliosis and microglia activation,
accompanied by neuronal cell death during the first days after the injury. The neuronal
cell death is associated with functional impairments (G1). The injection the siAQP4 after
jTBI (G2) induces a decrease in the AQP4 expression, which contributes to less entry of
water and edema (measured with T2 and ADC) and also fewer constraints on the BBB.
Therefore, these changes are associated with less astrogliosis and higher activation of the
microglia, which could be beneficial. With these improvements, the neuronal survival is
improved and accompanied by a better functional recovery after siAQP4 treatment (G2).
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Discussion
We report here for the first time that siAQP4 treatment is an effective mechanism
for reducing edema after jTBI and improves functional recovery even up to 60 days after
injury. Injection of siAQP4 reduced AQP4 expression by 30% and was associated with
significant decrements in edema formation, less BBB disruption, decreased astrogliosis,
increased microglia activation, reduced neuronal cell death as well as improved
neurological function during the acute phase after injury. We also observed that the
siAQP4 treated animals had improved hippocampal neuronal cell count and memory
recall at long-term: up to 60 days after injury as well. The uniqueness of our approach in
implementing siRNA targeting AQP4 to improve functional outcomes after jTBI at both
short and long-term after injury strongly suggests a potential future for clinical
development.
MRI (T2, ADC) was used to temporally monitor edema formation as is done
clinically after brain injury(8, 18). Our MRI data showed less post-traumatic edema after
siAQP4 treatment (Fig 2) as manifested by significantly reduced T2 values in siAQP4
compared to siGLO-treated rat pups at 3d, suggesting less water accumulation within the
lesion/perilesion and hippocampal tissues (Fig 2).
Beneficial effects of siAQP4 on water mobility as reflected by reduced ADC
values were also observed. ADC values are dramatically increased in the injury site and
likely correspond to cell death leading to an altered tissue matrix. This increase in ADC
at the lesion is decreased in siAQP4 compared to siGLO-treated rats, suggesting that
siAQP4 mitigates cell death at this early time point but not at 3d (Fig 2). However, in
adjacent tissues such as the hippocampus, the ADC values were also significantly

91

decreased, suggesting that siAQP4 may prevent cell death even at 3d in the hippocampus,
by limiting edema expansion. This hypothesis is supported by the increased numbers of
neurons in the siAQP4 treated animals at 3d (Fig 6). However, decreased ADC could also
be associated with a decrease in AQP4 expression on the astrocyte endfeet (Fig 1) at 3d
in accordance with our previous studies (14). In fact, decreased AQP4 expression has
been correlated with decreased ADC (14, 19) and increased AQP4 expression has been
correlated with increased ADC (20) in rats. This suggests that water diffusion is limited
by the decrease of AQP4 in the siAQP4-treated pups (Fig. 1). Together, the MRI data
demonstrate that siAQP4 treatment prevents edema formation with decreased T2 and
ADC values in the lesion and ipsilateral hippocampus. At 3d, T2 values are significantly
higher in the lesion/perilesion suggesting an increase in water content in the tissue due to
ongoing vasogenic edema formation in the untreated animals; while the decrease in the
siAQP4 treated rats suggest that siAQP4 prevents vasogenic edema formation. This
hypothesis is supported by the evidence of less BBB disruption (decreased IgG
extravasation, increased EBA and claudin-5 staining) in siAQP4 compared to siGLO
treated animals. In fact, injection of siAQP4 after jTBI may prevent water entry into
astrocytes and block subsequent swelling of these cells at 1d as indicated by the lower
values of ADC in siAQP4 animals compared to siGLO. Less osmotic stress on the
astrocytes may prevent BBB disruption by maintenance of the physical and mechanical
properties of the endothelial cells and also neurovascular unit (Fig 3, 4). Therefore, less
BBB disruption appears to be associated with less astrogliosis, which has been correlated
with the severity of brain injury (21).
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The next question was whether beneficial effects could still be observed at longterm after injury, and whether there were significant down regulation of AQP4. This is an
important question when considering the hypothesized biphasic and dual role that AQP4
plays not only in edema formation but also in edema clearance and maintaining regular
water homeostasis (22-23). It has been hypothesized and several experimental
observations hint that the presence of AQP4 is detrimental acutely after injury because
they contribute to the entry of water into the brain parenchyma so acute down regulation
of AQP4 may be beneficial, but chronic AQP4 depletion may be detrimental as AQP4 is
also needed for water clearance and maintenance of normal water homeostasis (24-27).
To this end, we performed a Western blot at 60d and also performed
immunohistochemistry to see if there were visible differences in AQP4 expression levels.
At 60d, we observed no differences in AQP4 levels or staining, thus injection of siAQP4
right after injury down-regulates AQP4 acutely but does not lead to chronic, long-term
depletion of AQP4. This is another beneficial effect of using siRNA as it allows
conditional down-regulation limited in the time of the target protein of interest.
The beneficial effects of siAQP4 treatment were also observed in the higher
number of neurons (NeuN positive cells) in siAQP4 compared to siGLO treated rats at
both acute and long-term after injury. These improvements led to improved neurological
outcomes at 1 and 3d in siAQP4 treated rats (Fig 7A, B). This improvement in motor
function was not visible at 7d, which may be a natural recovery or loss of some neurons
in perilesional cortex as shown at 60 days (Fig. 6). Interestingly, at 60d, there were a
significantly higher number of NeuN positive cells in the CA1 region of siAQP4
compared to siGLO; an effect of which can be observed in memory improvement. Our

93

unique data strongly suggest that the early decrease in AQP4 mitigates development of
secondary injuries such as edema resulting in chronic neuroprotection for the perilesional
structures, such as the hippocampus.
siAQP4 treatment resulted in greater microglial activation around the injection
site at 3d but not at 60d. Microglial activation after siAQP4 treatment is in accordance
with previous observations in brain injury models using AQP4 -/- mice (28-29). However,
acute microglial activation is hypothesized to be beneficial after injury (30), whereas a
chronic microglial activation is hypothesized to be detrimental (30), so it is likely that at
this time point, increased microglial activation due to siAQP4 treatment is contributing to
the beneficial effects observed in our model. This observation suggests a potential
relation between the level of AQP4 (Fig 1), astrogliosis and microglia activation (Fig 4,
7G1-G2).
We have previously speculated in a previous review (23) two of the possible
mechanisms responsible the relationship between AQP4 and microglial activation. The
first potential mechanism may be due to cross-talk that occurs between astrogliosis and
microglial activation (31). It is possible that the decreased extent of injury-induced
reactive astrogliosis is a result of knocking down AQP4 resulting in increased microglial
activity. A second possible mechanism behind the changes observed in post-traumatic
microglial activation in response to injection of siRNA against AQP4 may be because of
the stretch-activated chloride channels expressed in microglia cells (32). Stretchactivated; also known as swelling-activated chloride channels, are activated by osmotic
stress (33). Activation of these stretch-activated chloride channels contributes to the
maintenance of the non-activated (ramified) phenotype of microglia (32). Because AQP4
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is responsible for water transport, down-regulation of AQP4 through siRNA could have
decreased the osmotic stress on the microglia, thus limiting the activation of the swelling
activated chloride channels, resulting in microglial activation.
Both of these mechanisms are equally possible based on the data that we report,
because at 3d, when both AQP4 levels and astrogliosis are decreased in the siAQP4
treated rats, we observe an increase in microglial activation. However, at 60d, when
AQP4 levels and extent of astrogliosis are not changed between the groups, no significant
differences in microglial activation are observed.
Our results are in accordance with studies using knockout animals showing that
AQP4-/- had improved outcomes compared to WT mice in cerebral pathologies such as
hyponatremia (34), bacterial meningitis (34), water intoxication (25), focal cerebral
ischemia (25), spinal cord injury (35), and encephalomyelitis (36). Thus, the importance
of the development of an AQP4 inhibitor cannot be underestimated. However, as noted
earlier no specific effective drug directly against AQP4 is now available (8), despite
promising studies using agents such as bumetanide (11), acetazolamide (37-38) and
methazolamide (38-39). Our study provides a novel therapeutic strategy to successfully
target AQP4, leading to better outcomes after injury when edema is a prominent
pathological feature. Our findings are unique, demonstrating proof of concept that
siAQP4 treatment when given twice after injury reduces AQP4 expression by 30% and
this is sufficient to achieve beneficial functional outcomes on edema formation as well as
functional improvements, even long term after injury. Despite the relative modest
changes of each individual measurement, the combined effect on the neurovascular unit
is synergistic, with less neuronal cell death and functional improvements up to 60d post-
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jTBI. Furthermore, acute siAQP4 treatment does not lead to chronic or complete
depletion of AQP4, which in itself could be detrimental to the recovery and overall health
The next step would be to investigate the most efficient method to deliver an
AQP4 inhibitor to the brain without craniotomy. One potential administration route
would be intranasal delivery, which bypasses the BBB, is noninvasive, and easily
performed (40). Our novel findings provide compelling evidence for the effectiveness of
siAQP4 as a potential therapeutic agent not only for jTBI, but also for other brain
disorders in which edema is a significant contributing factor.

Disclosure/Conflict of Interest
The authors declare no conflict of interest.

96

References
1.

Faul M XL, Wald MM, Coronado VG. Traumatic brain injury in the United States:
emergency department visits, hospitalizations and deaths 2002-2006.: Atlanta (GA):
Centers for Disease Control and Prevention, National center for Injury Prevention
and Control2010.

2.

Pop V, Badaut J. A Neurovascular Perspective for Long-Term Changes After Brain
Trauma. Transl Stroke Res. 2011 Dec 1;2(4):533-45.

3.

Moran LM, Taylor HG, Rusin J, Bangert B, Dietrich A, Nuss KE, et al. Quality of
Life in Pediatric Mild Traumatic Brain Injury and its Relationship to
Postconcussive Symptoms. J Pediatr Psychol. 2011 Oct 12.

4.

Margulies S, Hicks R. Combination therapies for traumatic brain injury: prospective
considerations. J Neurotrauma. 2009 Jun;26(6):925-39.

5.

Ajao D, Pop V, Kamper J, Adami A, Rudobeck E, Huang L, et al. Traumatic brain
injury in young rats leads to progressive behavioral deficits coincident with altered
tissue properties in adulthood. J Neurotrauma. 2012 Jun 14.

6.

Fukuda AM, Pop V, Spagnoli D, Ashwal S, Obenaus A, Badaut J. Delayed increase
of astrocytic aquaporin 4 after juvenile traumatic brain injury: possible role in
edema resolution? Neuroscience. 2012 Oct 11;222:366-78.

7.

Pop V, Sorensen DW, Kamper JE, Ajao DO, Murphy MP, Head E, et al. Early
brain injury alters the blood-brain barrier phenotype in parallel with beta-amyloid
and cognitive changes in adulthood. J Cereb Blood Flow Metab. 2013
Feb;33(2):205-14.

8.

Badaut J, Ashwal S, Obenaus A. Aquaporins in cerebrovascular disease: a target for
treatment of brain edema? Cerebrovasc Dis. 2011;31(6):521-31.

9.

Badaut J, Brunet JF, Regli L. Aquaporins in the brain: from aqueduct to "multiduct". Metab Brain Dis. 2007 Dec;22(3-4):251-63.

10.

Tait MJ, Saadoun S, Bell BA, Papadopoulos MC. Water movements in the brain:
role of aquaporins. Trends Neurosci. 2008 Jan;31(1):37-43.

11.

Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S, Beckett E, et al.
Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the
loop diuretic bumetanide acting at an internal pore-occluding binding site. Mol
Pharmacol. 2009 Jul;76(1):105-12.

12.

Igarashi H, Huber VJ, Tsujita M, Nakada T. Pretreatment with a novel aquaporin 4
inhibitor, TGN-020, significantly reduces ischemic cerebral edema. Neurol Sci.
2011 Feb;32(1):113-6.

97

13.

Brower V. RNA interference advances to early-stage clinical trials. J Natl Cancer
Inst. 2010 Oct 6;102(19):1459-61.

14.

Badaut J, Ashwal S, Adami A, Tone B, Recker R, Spagnoli D, et al. Brain water
mobility decreases after astrocytic aquaporin-4 inhibition using RNA interference. J
Cereb Blood Flow Metab. 2011 Mar;31(3):819-31.

15.

Badaut J, Ashwal S, Tone B, Regli L, Tian HR, Obenaus A. Temporal and regional
evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pup
model of neonatal stroke. Pediatr Res. 2007 Sep;62(3):248-54.

16.

Hirt L, Ternon B, Price M, Mastour N, Brunet JF, Badaut J. Protective role of early
aquaporin 4 induction against postischemic edema formation. J Cereb Blood Flow
Metab. 2009 Feb;29(2):423-33.

17.

Gobbel GT, Bonfield C, Carson-Walter EB, Adelson PD. Diffuse alterations in
synaptic protein expression following focal traumatic brain injury in the immature
rat. Childs Nerv Syst. 2007 Oct;23(10):1171-9.

18.

Chastain CA, Oyoyo UE, Zipperman M, Joo E, Ashwal S, Shutter LA, et al.
Predicting outcomes of traumatic brain injury by imaging modality and injury
distribution. J Neurotrauma. 2009 Aug;26(8):1183-96.

19.

Meng S, Qiao M, Lin L, Del Bigio MR, Tomanek B, Tuor UI. Correspondence of
AQP4 expression and hypoxic-ischaemic brain oedema monitored by magnetic
resonance imaging in the immature and juvenile rat. Eur J Neurosci. 2004
Apr;19(8):2261-9.

20.

Tourdias T, Dragonu I, Fushimi Y, Deloire MS, Boiziau C, Brochet B, et al.
Aquaporin 4 correlates with apparent diffusion coefficient and hydrocephalus
severity in the rat brain: a combined MRI-histological study. Neuroimage. 2009
Aug 15;47(2):659-66.

21.

Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV. Essential protective
roles of reactive astrocytes in traumatic brain injury. Brain. 2006 Oct;129(Pt
10):2761-72.

22.

Berezowski V, Fukuda AM, Cecchelli R, Badaut J. Endothelial Cells and
Astrocytes: A Concerto en Duo in Ischemic Pathophysiology. Int J Cell Biol.
2012;2012:176287.

23.

Fukuda AM, Badaut J. Aquaporin 4: a player in cerebral edema and
neuroinflammation. J Neuroinflammation. 2012;9:279.

24.

Kimura A, Hsu M, Seldin M, Verkman AS, Scharfman HE, Binder DK. Protective
role of aquaporin-4 water channels after contusion spinal cord injury. Ann Neurol.
2010 Jun;67(6):794-801.

98

25.

Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, et al. Aquaporin-4
deletion in mice reduces brain edema after acute water intoxication and ischemic
stroke. Nat Med. 2000 Feb;6(2):159-63.

26.

Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC. Three distinct
roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys
Acta. 2006 Mar 10.

27.

Tait MJ, Saadoun S, Bell BA, Verkman AS, Papadopoulos MC. Increased brain
edema in aqp4-null mice in an experimental model of subarachnoid hemorrhage.
Neuroscience. 2010 Apr 28;167(1):60-7.

28.

Shi WZ, Zhao CZ, Zhao B, Zheng XL, Fang SH, Lu YB, et al. Aquaporin-4
deficiency attenuates acute lesions but aggravates delayed lesions and microgliosis
after cryoinjury to mouse brain. Neurosci Bull. 2012 Feb;28(1):61-8.

29.

Lu DC, Zador Z, Yao J, Fazlollahi F, Manley GT. Aquaporin-4 Reduces PostTraumatic Seizure Susceptibility by Promoting Astrocytic Glial Scar Formation in
Mice. J Neurotrauma. 2011 Sep 22.

30.

Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurotherapeutics. 2010
Oct;7(4):366-77.

31.

Liu W, Tang Y, Feng J. Cross talk between activation of microglia and astrocytes in
pathological conditions in the central nervous system. Life Sci. 2011 Aug 1;89(56):141-6.

32.

Eder C, Klee R, Heinemann U. Involvement of stretch-activated Cl- channels in
ramification of murine microglia. J Neurosci. 1998 Sep 15;18(18):7127-37.

33.

Lewis RS, Ross PE, Cahalan MD. Chloride channels activated by osmotic stress in
T lymphocytes. J Gen Physiol. 1993 Jun;101(6):801-26.

34.

Papadopoulos MC, Verkman AS. Aquaporin-4 gene disruption in mice reduces
brain swelling and mortality in pneumococcal meningitis. J Biol Chem. 2005 Apr
8;280(14):13906-12.

35.

Saadoun S, Bell BA, Verkman AS, Papadopoulos MC. Greatly improved
neurological outcome after spinal cord compression injury in AQP4-deficient mice.
Brain. 2008 Apr;131(Pt 4):1087-98.

36.

Li L, Zhang H, Verkman AS. Greatly attenuated experimental autoimmune
encephalomyelitis in aquaporin-4 knockout mice. BMC Neurosci. 2009;10:94.

37.

Huber VJ, Tsujita M, Yamazaki M, Sakimura K, Nakada T. Identification of
arylsulfonamides as Aquaporin 4 inhibitors. Bioorg Med Chem Lett. 2007 Mar
1;17(5):1270-3.

99

38.

Tanimura Y, Hiroaki Y, Fujiyoshi Y. Acetazolamide reversibly inhibits water
conduction by aquaporin-4. J Struct Biol. 2009 Apr;166(1):16-21.

39.

Huber VJ, Tsujita M, Kwee IL, Nakada T. Inhibition of aquaporin 4 by antiepileptic
drugs. Bioorg Med Chem. 2009 Jan 1;17(1):418-24.

40.

Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH, 2nd. Delivery of interferonbeta to the monkey nervous system following intranasal administration.
Neuroscience. 2008 Mar 27;152(3):785-97.

100

CHAPTER FOUR
SMALL INTERFERENCE RNA AGAINST CONNEXIN-43 AFTER JUVENILE
TRAUMATIC BRAIN INJURY LEADS TO FUNCTIONAL RECOVERY

By
Andrew M Fukudaa,b, Nina Nishiyamac, Germaine Parisc, Jerome Badauta,b

a

Department of Physiology, Loma Linda University, Loma Linda, CA 92354

b

Department of Pediatrics, Loma Linda University Medical Center, Loma Linda, CA

92350
c

Loma Linda University, Loma Linda, CA 92354

101

Abstract
Juvenile traumatic brain injury (jTBI) is the leading cause of death and disability
for children and adolescents in the United States of America, but there is no
pharmacological treatment after injury. Perivascular astrocytes and the astrocyte network
is known to be affected by many brain pathologies and is hypothesized to be responsible
for the secondary injury cascade, where cells and regions further from the actual site of
injury are affected detrimentally. One such secondary injury pathway is blood brain
barrier disruption and edema, for which several astrocyte proteins are highly likely to be
responsible. We have previously published one of these key perivascular astrocyte
proteins, aquaporin 4 (AQP4), to be increased after jTBI at multiple timepoints after
injury and have shown that decrease of AQP4 expression with small interference RNA
against AQP4 mitigates edema formation and the presence of reactive astrocytes after
juvenile traumatic brain injury (jTBI). Due to the proximity of the AQP4 water channels
and gap junctions and the possibility of water diffusion via gap junctions, the potential
role of the astrocytic gap junction forming connexins were studied. In the first part of the
experiment, changes in proteins involved in the formation of the astrocyte network gap
junctions: Cx30 and Cx43, were evaluated after jTBI. In a second experiment, we
evaluated the effect of small interference RNA against Cx43 on edema formation,
reactive astrogliosis, and motor recovery.
Cx proteins make up the gap junctions which connect neighboring astrocytes,
allowing for the flow of ions, metabolites, neurotransmitters, and water. It has been
speculated that these Cxs are responsible for the secondary injury cascade because of this
flow from the primary injury site to distant sites, and AQP4 may be functionally coupled
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to Cx43. We observed that Cx43 was increased at 3d, 7d, and 60d in the perilesional
cortex, and Cx30 was increased at 1d and 3d. We also observed Cx43 to be increased at
3d and 7d in the CA1 and Cx30 increased at 1d in the same region. Additionally,
astrogliosis was increased after jTBI at 1d, 3d, 7d, and 60d as seen via GFAP analysis.
siCx43 did result in improved motor recovery and decreased GFAP immunoreactivity but
did not result in differences in edema formation as measured via T2 (water content) or
ADC (water mobility) using MRI at 1d or 3d. From this, we can speculate that although
decreasing Cx43 has beneficial roles, the protein may not be contributing to the initial
edema formation phase after jTBI in our model.
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Introduction
In the US, the annual incidence of non-military related traumatic brain injury
(TBI) is approximately 1.7 million, of which 327,000 are hospitalized and 52,000 die
(Faul et al., 2010). Juvenile traumatic brain injury (jTBI), which is the leading cause of
death and disability in children and adolescents (Faul et al., 2010), is of especially severe
concern because the population group most affected (emergency department visit,
hospitalization, and death) are those younger than five, followed by teenagers 15 – 19
years old (Faul et al., 2010). The effect of jTBI is two-fold: primary injury and secondary
injury. Primary injury results mainly from the direct and immediate biomechanical
disruption of the brain tissue. Secondary injuries are the result of an indirect and more
delayed molecular mechanism occurring at sites directly surrounding the impacted site
and evolves toward regions at a distance from the initial impact site (Bauer and Fritz,
2004). Primary injury can only be lessened by taking preemptive caution such as wearing
helmets, so the goal of potential therapeutics is to lessen the damage caused by the
secondary injury (Morales et al., 2005). Some of the major determiners for secondary
injury cascade are blood brain barrier (BBB) disruption and edema and cellular swelling
(Bauer and Fritz, 2004). However, no pharmacological treatments exist against this
ruthless epidemic.
Although various cell types such as neurons, oligodendrocytes, and endothelial
cells swell after injury, astrocytes are the first cell types to swell, and the swelling lasts
the longest; in fact, perivascular astrocyte endfeet can swell within minutes after injury
(Grange-Messent and Bouchaud, 1994), and this swelling may spread from primary
injury site to distant sites: thus being responsible for the secondary injury cascade.
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Therefore the need to study the astroglial pathophysiology after jTBI is necessary to
successfully target these injury cascades such as edema. We have previously published a
study in which the expression level of aquaporin 4 (AQP4) - a key perivascular astrocyte
endfeet protein responsible for water homeostasis under normal condition and the edema
process after injury - was shown to increase at multiple timepoints after jTBI that
coincided with both the peak of edema formation at 3d and edema resolution at 7d
(Fukuda et al., 2012a), and early downregulation of this protein via small interference
RNA after brain injury showed beneficial effects after jTBI both during the acute and
chronic phase due to decreased edema (Fukuda et al., 2013).
However, the aforementioned spread of secondary injury is not only due to the
entrance of water from the peripheral blood stream to the brain parenchyma across
AQP4, but most likely also due to the astrocyte network, which is mediated by gap
junctions. Astrocytic gap junctions form the connection between neighboring astrocytes,
allowing the flow of various molecules and water, and the proteins that make up these
gap junctions are the connexins (Giaume et al., 2010). Six connexin proteins form a
connexon, which is a hemichannel, and when a hemichannel from one cell attaches with
another hemichannel of an adjacent cell, that is called a gap junction. Therefore, 12
connexins make up one gap junction (Giaume et al., 2010). The connexin subtypes are
named according to their molecular weight, thus Cx43 has a molecular weight of 43
kiloDalton and Cx30 has that of 30 kiloDalton. Of these connexins, Cx43, which is
predominantly astrocytic (Giaume et al., 2010; Rash et al., 2001), is one of the most
studied connexin in the brain and highly expressed in astrocytes, which far outnumber
other cell types in the brain, including neurons (Sofroniew and Vinters, 2010). Connexin
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43 form a hemichannel that has an aqueous pore and selectively permits flow of small
endogenous molecules such as second messengers, amino acids, nucleotides, small
peptides, and also water (Giaume et al., 2010; Goodenough and Paul, 2003; Herve and
Derangeon, 2012; Wallraff et al., 2006). The hypothesized spread of detrimental factors
and toxic metabolites such as sodium and calcium ions, apoptotic factors,
lysophospholipids, cAMP, and IP3 from the primary injury site to more distant sites
mediated by gap junctions is referred to as “bystander effect (Andrade-Rozental et al.,
2000; Perez Velazquez et al., 2003),” and several studies have shown astrocytic connexin
levels to be increased in affected brain regions after cerebrovascular pathologies such as
stroke (Chew et al., 2010). However, no study has been done to characterize the levels of
the astroglial gap-junction forming connexins after jTBI.
Several studies using general gap junction inhibitors such as carbenoxolone and
octanol have shown better outcome in several ischemic stroke models (Andersson et al.,
2011; Frantseva et al., 2002; Perez Velazquez et al., 2006; Rawanduzy et al., 1997). Of
note, Wu et al. have recently shown that injection of antisense-oligodeoxynucleotide
against Cx43 (AS-ODN Cx43) into the lateral ventricle one hour prior to TBI in adult rats
led to decreased edema (as measured via the wet-dry brain weight method) and decreased
astrogliosis up to 48 hrs after injury compared to control group (Wu et al., 2013).
But to date, there is no study done for a jTBI model in which Cx43 was specifically
inhibited. We have previously shown small interference RNA against aquaporin 4,
another astrocyte protein essential in the edema process after jTBI (Fukuda et al., 2012a),
to be beneficial after injury (Fukuda et al., 2013). Therefore, in this study, the therapeutic
potential of small interference RNA against Cx43 (siCx43) will be pursued after jTBI.
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Methods to inhibit Cx43 specifically by targeting its mRNA have been effective in
several in vitro models (Chew et al., 2010), and the use of siCx43 in vivo in a model of
corneal endothelial injury have also shown beneficial results (Grupcheva et al., 2012).
Thus, siCx43 would be a specific and effective method to downregulate Cx43 protein to
study the functional behavior outcome after jTBI. Furthermore, edema, astrogliosis, and
blood brain barrier (BBB) disruption will be studied because they are common
pathophysiological targets of jTBI influenced by the astrocyte network (Fukuda et al.,
2013).

Materials and Methods
General Experimental Setup
Two groups of studies were planned and performed. The first groups of studies
were constructed in order to examine the changes in the astrocyte network connexin
proteins (Cx43, Cx30) and GFAP levels after juvenile traumatic brain injury. The second
group of studies were constructed in order to examine the effect of small interference
RNA against Cx43 (siCx43) injection after juvenile traumatic brain injury on astrocyte
network connexin proteins (Cx43, Cx30), GFAP, blood brain barrier permeability (IgG),
edema (ADC, T2), and behavior/motor activities.

Animal Care
All animal care and experiments were conducted according to the Guidelines for
Care and Use of Experimental Animals approved by Loma Linda University. All
protocols and procedures were in compliance with the U.S. Department of Health and
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Human Services Guide and were approved by the Institutional Animal Care and Use
Committee of Loma Linda University. Postnatal day 17 (P17) Sprague Dawly rat pups
were housed in a temperature controlled (22-25oC) animal facility on a 12-hour light/dark
cycle with standard lab chow and water ad libitum.

siRNA Preparation
An in vivo Cx43 silencing protocol was adapted as described in our previous
studies.(Badaut et al., 2011) Briefly, SMART-pool® containing 4 siRNA-duplexes
against Cx43 (400ng, siCx43, Dharmacon Research) and non-targeted siRNA (siGLO
RISC-free-control-siRNA, Dharmacon Research) were mixed with interferin® (Polypustransfection, Illkirch, France) diluted in a saline solution (0.9%) containing 5% glucose
for a final volume of 5 L and incubated on ice for 20 min before injection.

Controlled Cortical Impact and siRNA Injection
Controlled cortical impact (CCI) was carried out on P17 old rat pups as
previously described (Ajao et al., 2012; Fukuda et al., 2012a; Fukuda et al., 2013). Rats
were anesthetized with isoflurane and placed in a stereotaxic apparatus (David Kopf
Instrument, Tujunga, USA). A 5 mm diameter craniotomy over the right hemisphere 3
mm posterior from bregma and 4 mm lateral to midline was performed. Animals were
subjected to CCI using an electromagnetic impactor with a 2.7 mm round tip set to
impact with a velocity of 6 m/s and a depth of 1.5 mm below the cortical surface (Leica,
Richmond, IL). Sham animals received the craniotomy, but without the cortical impact.
The craniotomy did not cause damage to the dura mater and was intact in both the jTBI
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and sham groups. After CCI, none of the animals had major bleeding or cortical tissue
herniation.
siRNA administration was performed as previously described (Fukuda et al.,
2013). Injection of siRNA was performed 10 min after the injury lateral to the site of the
impact using a 30-gauge needle on a Hamilton syringe (3 mm posterior to bregma, 6 mm
lateral to midline, and 1.0 mm below cortical surface). The syringe was attached to a
nanoinjector (Leica, Richmond, IL) and 4 L of either siCx43 or siGLO was
administered at a rate of 0.5 L/min. After suturing, all pups were placed on a warm
heating pad for recovery before being returned to their dams. A second siRNA injection
was repeated 2 days after the CCI in all pups that received siRNA using the same
injection protocol.

Magnetic Resonance Imaging (MRI)
MRI was performed at 1 and 3d to follow the process of edema formation and to
observe water content and water mobility at the peak of edema in this model (Fukuda et
al., 2012a; Fukuda et al., 2013). Pups were lightly anesthetized using isoflurane (1.0%)
and imaged on a Bruker Avance 11.7 T (Bruker Biospin, Billerica, MA)(Fukuda et al.,
2013) Two imaging data sets were acquired: 1) a 10 echo T2- and 2) a diffusion
weighted imaging (DWI) sequence in which each sequence collected 20 coronal slices (1
mm thickness and interleaved by 1 mm). The 11.7T T2 sequence had the following
parameters: TR/TE = 2357.9 / 10.2 ms, matrix = 128 x 128, field of view (FOV) = 2 cm,
and 2 averages. The DWI sequence had the following parameters: TR/TE = 1096.5 / 50
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ms, two b-values (116.960, 1044.422 s/mm2), matrix = 128 x 128, FOV = 2 cm, and 2
averages.

Region of Interest (ROI) and Volumetric Analysis
T2 and apparent diffusion coefficient (ADC) values were quantified using
previously published standard protocols (Badaut et al., 2011). Regions of interest (ROIs)
were placed on the imaging section with the maximally detected injury using Cheshire
(Parexel International Corp. Waltham, MA). Lesion and ipsilateral hippocampus were
delineated on T2 images and overlaid onto corresponding T2 and ADC maps. The mean,
standard deviation, and area for each ROI were extracted.

Behavioral Testing
Foot-fault and rotarod testing was performed at 1d and3d in both the siCx43 and
Control group. The foot-fault test evaluated sensorimotor, coordination, and
proprioception while the rotarod test evaluated sensorimotor coordination and balance as
previously reported in our earlier studies.(Ajao et al., 2012) All tests at each time-point
were carried out on siGLO and siCx43 treated rats within a 3-hours morning time-block
(8 – 11 am). siGLO and siCx43 treated rats were interleaved in testing sequence. To
further control potential confounds, the same tests were administered in the same order at
all of the time points, by the same investigators blinded to the experimental groups.
Foot-fault testing was carried out on an elevated platform (50 cm X 155 cm,
ClosetMaid, Ocala, FL) with parallel wire bars 1.5 cm apart and raised 100 cm above the
floor. Rats were placed in the middle of the platform to freely roam around. When a
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rodent’s paw (fore- or hindlimb) slipped completely through the wire mesh, it was
considered as an individual fault. The average foot-fault score was calculated from the
total number of faults from two 60 sec trials.
Rotarod evaluation was performed on all the animals at 1d and 3d (SD
Instruments, San Diego, CA). A rotating 7 cm-wide spindle with a continuous speed
(10RPM and 20 RPM) was used to evaluate performance during two trials per speed.
Latency to fall was the outcome measure used as a measure of motor coordination and
balance. The maximum time spent on the test was 60s, if the rat did not fall, at which
point the rotation was halted and the rat was taken off of the spindle. The average time
from the 2 trials was calculated and expressed in total time (s) for 2 trials.

Immunohistochemistry and Image Analysis
For the first set of experiments in which the connexin and GFAP expression was
studied between animals who received CCI and sham group, at 1d, 3d, 7d, and 60d
animals were transcardially perfused with 4% paraformaldehyde and brains were
extracted and put in 30% sucrose for 48 hours, then stored in -22°C. Coronal sections
were cut at 20 μm thickness at -22°C on a cryostat (Leica, Richmond, IL) and mounted
on slides for immunohistochemical analysis (Badaut et al., 2007; Badaut et al., 2011; Hirt
et al., 2009). For the second set of experiments in which siRNA was injected after jTBI,
animals were transcardially perfused at 3d.
The primary antibodies used for immunohistochemistry were rabbit polyclonal
antibodies for Cx43 (1:100, Abcam, Cambridge, MA), rabbit polyclonal antibodies for
Cx30 (1:100, Abcam, Cambridge, MA), and chicken polyclonal antibodies for GFAP
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(1:1000, Millipore, Billerica, MA). The secondary antibodies used were IRDye 800
conjugated affinity purified donkey-anti-rabbit IgG (1:1000, Rockland, Gilbertsville,
PA), IRDye 680 conjugated affinity purified donkey-anti-chicken IgG (1:1000, Rockland,
Gilbertsville, PA), Alexa 594 conjugated affinity purified goat anti-rabbit IgG (1:1000,
Invitrogen, Carlsbad, CA), Alexa 488 conjugated affinity purified goat anti-rabbit IgG
(1:1000, Invitrogen, Carlsbad, CA), Alexa 568 conjugated affinity purified goat antichicken IgG (1:1000, Invitrogen, Carlsbad, CA), and Alexa 488 conjugated affinity
purified goat anti-chicken IgG (1:1000, Invitrogen, Carlsbad, CA).
For immunohistochemistry, sections were washed with PBS, blocked with 1%
BSA in PBS, incubated with the respective primary antibodies in PBS containing 0.1%
Triton X-100 and 1% bovine serum albumin overnight, then incubated for 2 hours at
room temperature with affinity purified secondaries conjugated to the desired wavelength
in PBS containing 0.1% Triton X-100 and 1% bovine serum albumin. After washing,
sections were scanned on an infra-red (IR) scanner (Odyssey) to quantify fluorescence for
the different ROIs as previously described (Badaut et al., 2011) or imaged under a
confocal laser microscope (Zeiss). For sections to be imaged under a confocal
microscope, sections on glass slides were cover-slipped with anti-fading medium
VectaShield containing 4’,6-diamidino-2-phenylindole (DAPI) (Vector, Vector
laboratories, Burlingame, CA, USA).
All image acquisition parameters for the same proteins were kept constant for all
of the animals for analysis and visualization purposes and all analysis was carried out in a
non-biased, blinded manner. For the analysis of Cx43, Cx30, and GFAP, the following
method was used as previously described (Fukuda et al., 2013). The slides with the above
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mentioned primary antibodies with the secondaries conjugated to the infrared wavelength
(680 or 800 nm) were scanned on an infrared scanner (Odyssey, Lincoln, NE), and
images were saved with a resolution of 21 μm per pixel. Identical circular regions of
interests (ROIs) were drawn in the perilesional cortex and in the ipsilateral CA1 at three
different bregma levels (-1.40mm, -2.56mm, and -3.80mm): the bregma level where
lesion area was largest, one slice anterior and one posterior. The average fluorescence of
these regions of interests was calculated to show immunoreactivity of each of the protein
and between groups.
Negative control staining where the primary antibody or secondary antibody was
omitted showed no detectable labelling.
For immunoglobulin (IgG) extravasation immunohistochemistry, sections were
washed with PBS, blocked with 1% BSA in PBS, then incubated for 2 hours at room
temperature with IRDye 800 conjugated affinity purified goat-anti-rat IgG (1:500,
Rockland, Gilbertsville, PA) in PBS containing 0.1% Triton X-100 and 1% bovine serum
albumin. After washing, sections were scanned on an infra-red (IR) scanner (Odyssey) to
quantify fluorescence for the different ROIs and also to measure the area of extravasation
divided by the total brain area per ROI.

Western Blot
At 3d and 7d, the brains were freshly extracted from another set of sham and jTBI
animals, the cortical tissue adjacent to the site of impact was collected and frozen for
western blot analysis as previously published (Fukuda et al., 2012a). Tissues were placed
in a tube with RIPA buffer with protease inhibitor cocktail (PIC, Roche, Basel,
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Switzerland) and sonicated for 30s and stored in -20C. These samples were then assayed
for total protein concentration by bicinchoninic acid assay (BCA, Pierce Biotechnology
Inc., Rockford, IL). Ten micrograms of protein was then subjected to SDS
polyacrylamide gel electrophoresis on a 4–12% gel (Nupage, Invitrogen, Carlsbad, CA,
USA). Proteins were then transferred to a polyvinylidene fluoride membrane
(PerkinElmer, Germany). The blot was incubated with a rabbit polyclonal antibody
against Cx43 (1:1000, Abcam, Cambridge, MA) or Cx30 (1:1000, Abcam, Cambridge,
MA) and a monoclonal antibody against tubulin (Sigma, Switzerland, 1:25,000) in
Odyssey blocking buffer (LI-COR, Bioscience, Germany) for 2 h at room temperature.
After washing in PBS for 3x10min, the blot was incubated with two fluorescencecoupled secondary antibodies (1:10,000, anti-rabbit Alexa-Fluor-680 nm, Molecular
Probes, Oregon and anti-mouse infra-red-Dye-800-nm, Roche, Germany) for 2 h at room
temperature. After washing in PBS, the degree of fluorescence was measured using an
infra-red scanner (Odyssey, LI-COR, Germany) as previously published (Fukuda et al.,
2013). The value of Cx43 and Cx30 was normalized to tubulin and compared between
jTBI and sham at each timepoint.

Statistics
One way ANOVA was used for immunohistochemistry analysis and western blot
to compare the mean between the sham and jTBI group at each timepoint. One way
ANOVA was used for immunohistochemistry analysis to compare the mean between
siGLO and siCx43 group as well. Two-way repeated measures analysis of variance with a
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post hoc Bonferroni test was used for the behavior and MRI data. A p value less than
0.05 was considered to be statistically significant.

Results
Chronic Increase of Connexin 43 Expression after jTBI
Cx43 protein changes were first evaluated using infra-red immunohistochemistry
at 1d, 3d, 7d and 60d post-jTBI. At 1d, there was no significant difference (Fig. 1A).
However, during the edema period from 3d to 7d in this model (Fukuda et al., 2012b),
increase in the level of Cx43 immunofluorescence at 3d and 7d compared to age-matched
sham operated animals in the perilesional cortex was observed (Fig. 1A, p<0.05).
Furthermore, the increase of the Cx43 immunoreactivity was still observed up to 60d,
suggesting a signature involvement of the reactive astrocytes. Similar increase at 3d was
observed (p<0.05) in ipsilateral hippocampus located under the site of the impact, when
compared to age-matched sham operated animals (Fig. 1B). However, after 3d there were
no significant changes in Cx43 in the hippocampus. No differences were observed
between groups in the contralateral cortex and hippocampus.
The immunohistochemistry data was confirmed by western blot analysis for the
time points 3 (Fig. 1C) and 7days (Fig. 1D). Cx43 western blot showed an expected band
at 43 kda in both groups, with a higher intensity for the jTBI group compared to sham
animals. The level of intensity of Cx43 was normalized to beta-tubulin, used as a
housekeeping protein (Fig. 1C-F). The quantification of the band showed a significant
increase for the two time points, with 30% increase at 3d (Fig. 1E) and 200% increase at
7d (Fig. 1F).

115

Figure 1. Chronic increase of Connexin 43 expression after jTBI. (A) Cx43 staining
quantification in the perilesional cortex showed increased Cx43 immunoreactivity at 3d,
7d, and 60d after jTBI as compared to sham. (B) Cx43 immunoreactivity in the ipsilateral
hippocampus showed a significant increase at 3d (*p<0.05). Western blot of Cx43 at 3d
(C) and 7d (C) shows a distinct band of Cx43 at around 43kDa. jTBI shows a
significantly higher expression of Cx43 at both 3d (E) and 7d (F) compared to sham.
(Cx43, connexin 43; kDa, kilo Dalton; jTBI, juvenile traumatic brain injury; *p<0.05).
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Connexin 30 is Upregulated Acutely after jTBI
Cx30 protein changes were first evaluated using infra-red immunohistochemistry
at 1d, 3d, 7d and 60d post-jTBI. At 1d and 3d, a significant increase was observed in
immunoreactivity in the perilesional cortex in the injured animals compared to agematched sham operated control animals (Fig. 2A, p<0.05). However, no significant
difference was observed in the perilesional cortex at 7d and 60d. In the ipsilateral
hippocampus located under the site of the impact, a significant increase in Cx30
immunoreactivity was observed at 1d (p<0.05) when compared to age-matched sham
operated animals but not at the other timepoints (Fig. 2B).
The immunohistochemistry data was confirmed by western blot analysis for the
time points 3 (Fig. 2C) and 7days (Fig. 2D). Cx30 western blot showed an expected band
at 30 kDa in both groups, with a higher intensity for the jTBI group compared to sham
animals at 3d. The level of intensity of Cx43 was normalized to beta-tubulin, used as a
housekeeping protein (Fig. 2C-F). The quantification of the band showed a 200%
increase at 3d (Fig. 2E, p<0.05), but no significant difference at 7d (Fig. 2F).
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Figure 2. Connexin 30 is upregulated acutely after jTBI. (A) Cx30 staining quantification
in the perilesional cortex showed increased Cx30 immunoreactivity at 1d and 3d after
jTBI as compared to sham. (B) Cx30 immunoreactivity in the ipsilateral hippocampus
showed a significant increase at 1d (*p<0.05). Western blot of Cx30 at 3d (C) and 7d (C)
shows a distinct band of Cx30 at around 30kDa. jTBI shows a significantly higher
expression of Cx30 at 3d (E) but not at 7d (F) compared to sham. (Cx30, connexin 30;
kDa, kilo Dalton; jTBI, juvenile traumatic brain injury; *p<0.05).
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Astrogliosis Occurs and is Maintained after jTBI.
The extent of astrogliosis was studied via glial fibrillary astrocytic protein
(GFAP)-immunoreactivity (Fig. 3). GFAP is found in the astrocyte cytoskeleton and
routinely used for studying astrocytes. GFAP staining intensity was increased in the
perilesional cortex in jTBI induced rat pups compared to the age-matched control group
at 1d, 3d, 7d, and 60d (Fig. 3A). Unlike the perilesional cortex in which a significant
increase in astrogliosis was observed at all timepoints tested, in the ipsilateral
hippocampus, a significant increase (p<0.05) was only observed at 1d (Fig. 6C).
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Figure 3. Astrogliosis occurs and is maintained after jTBI. (A) GFAP staining
quantification in the perilesional cortex showed increased GFAP immunoreactivity at 1d,
3d, 7d, and 60d after jTBI as compared to sham. (B) GFAP immunoreactivity in the
ipsilateral hippocampus showed a significant increase at 1d (*p<0.05). (GFAP, glial
fibrillary acidic protein; jTBI, juvenile traumatic brain injury; *p<0.05).
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siCx43 Injection Reduces Cx43 Expression
Acutely after Injury
Once the normal pathological change of astrocyte connexin was studied using
jTBI and sham control animals, the next step was to test the effect of decreasing this
protein. Because Cx43 expression after injury has been studied more extensively and thus
far has been proposed to play a more central role in pathophysiological cascades after
injury (Chew et al., 2010; Grupcheva et al., 2012; Nakase et al., 2004; Ohsumi et al.,
2010; Theodoric et al., 2012; Wu et al., 2013; Yoon et al., 2010), for our study Cx43 was
chosen as the potential target. For this purpose, siRNA against Cx43 (siCx43) was
injected in the lesion site after injury. To see if siCx43 was effective in decreasing Cx43
expression, Cx43 protein changes were evaluated using infra-red immunohistochemistry
at 3d post-jTBI. Injection of siCx43 induced a significantly lower level of Cx43
compared to siGLO control group 3d after the injury (19% decrease) in the perilesional
cortex (Fig. 4A), but no significant difference was observed in the ipsilateral
hippocampus (Fig. 4B).
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Figure 4. siCx43 Injection Reduces Cx43 Expression Acutely after Injury. Cx43
immunoreactivity was quantified and confirmed a significant decrease in Cx43immunoreactivity in the siCx43 compared to siGLO treated rats in the (A) perilesional
cortex but not in the (B) ipsilateral hippocampus (*, p<0.05). (Cx43; connexin 43).
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siCx43 Injections did not Result in Changes in
Cx30 Expression Acutely after Injury
To test whether siCx43 injection had any acute effect on Cx30 expression due to
either off targets effects or a compensatory mechanism, Cx30 protein changes were
evaluated using infra-red immunohistochemistry at 3d post-jTBI as well. Injection of
siCx43 did not result in a significant Cx30 immunoreactivity changes compared to siGLO
control group 3d after the injury in neither the perilesional cortex (Fig. 5A) nor the
ipsilateral hippocampus (Fig. 5B).
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Figure 5. siCx43 Injections did not Result in Changes in Cx30 Expression Acutely after
Injury. Cx30 immunoreactivity was quantified and showed no significant decrease in
Cx30-immunoreactivity in the siCx43 compared to siGLO treated rats in both the (A)
perilesional cortex and (B) ipsilateral hippocampus. (Cx30; connexin 30).
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siCx43 Injection Resulted in Improved
Behavior Outcome after jTBI
To test whether Cx43 downregulation resulting from siCx43 injection had a
beneficial effect regarding motor function recovery after injury, foot-fault and rotarod
testing was performed at 1d and 3d. The foot-fault test evaluated sensorimotor,
coordination and proprioception while the rotarod test evaluated sensorimotor
coordination and balance. siCx43 pups had fewer foot-faults at 1 and 3d (respectively
24% and 36%, p < 0.05, Fig 6A). Although a trend was observed in which siCx43
animals were staying on the rotarod longer than siGLO control animals, the difference
was not statistically significant (Fig. 6B).
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Figure 6. siCx43 Injection Resulted in Improved Behavior Outcome after jTBI. siCx43treated pups had better functional outcomes as revealed by the foot-fault test. siCx43
group had significantly fewer foot faults than siGLO treated animals at day 1 (24%) and
day 3 (36%) after jTBI (*, p < 0.05) (A). However, siCx43 animals’ performance on the
rotarod did not significantly differ with that of siGLO at neither 1d nor 3d (B).

126

siCx43 Animals had Reduced Astrogliosis after jTBI
Transgenic mice with Cx43 knocked out was associated with a decreased GFAP
expression (Nakase et al., 2003) and Cx43 blockade has been shown to decrease GFAP
immunoreactivity after injury (Wu et al., 2013). To study whether this was still valid in
our model of jTBI, GFAP-infrared immunohistochemistry was used to assess the effects
of siCx43 on neuroinflammation /astrogliosis after jTBI. There was a 17% decrease in
GFAP immunofluorescence in the perilesional cortex of the siCx43 rat pups as compared
to the siGLO control group (p<0.05, Fig. 7A). However, no significant difference was
observed in the ipsilateral hippocampus (Fig. 7B).
Because astroglial connexins have been hypothesized to play a role in BBB
permeability (Ezan et al., 2012) and BBB disruption is a major pathophysiology after
jTBI, the BBB permeability was assessed via immunoglobulin G (IgG)
immunohistochemistry. Under normal circumstance IgG is not observed in the brain,
however IgG is observed after injury in which the BBB is disrupted because IgG is
extravasated from the peripheral bloodstream into brain tissue. IgG extravasation was
calculated as the percentage of the area of IgG staining to total brain slice area. At 3d,
there was no significant difference in the extent of IgG extravasation between siCx43
(18.92%) and siGLO control (18.40%) (Fig. 7C), signifying no difference in the extent of
BBB permeability between treated and untreated animals.
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Figure 7. siCx43 animals had reduced astrogliosis after jTBI. GFAP staining
quantification in the (A) perilesional cortex showed significant decrease in siCx43
compared to siGLO animals but not in (B) the ipsilateral hippocampus. (C) The extent of
IgG extravasation was not significantly different between siGLO and siCx43 animals,
signifying most likely the same extent of BBB disruption/permeability (*p<0.05).
(GFAP, glial fibrillary acidic protein; jTBI, juvenile traumatic brain injury; IgG,
Immunoglobulin G; *p<0.05).
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Significant Difference in T2 and ADC was not Observed
Acutely between siCx43 and Control
To address the question of whether decreased Cx43 protein level via siCx43
injection would alter edema formation, MRI was utilized to obtain T2 and ADC values at
1d and 3d. T2 was chosen as a measurement of edema/water content and ADC was used
as a measurement of water mobility. T2 and ADC values were analyzed in the
perilesional cortex and ipsilateral hippocampus at 1d and 3d in all of the animals from the
siCx43 and siGLO groups. In the perilesional cortex, there was no significant difference
in T2 values between siGLO (1d – 116.58 +/- 6.82 ms; 3d – 93.54 +/- 3.47 ms) and
siCx43 (1d – 107.75 +/- 7.85 ms; 3d- 101.27 +/- 7.86 ms) (Fig. 8A). Similarly, in the
ipsilateral hippocampus, no significant difference was observed between siGLO (1d 121.53 +/- 7.45 ms; 3d - 99.29 +/- 3.01 ms) and siCx43 (1d – 114.66 +/- 8.47 ms; 3d –
109.45 +/- 7.45ms) (Fig. 8B).
For ADC values in the perilesional cortex, no significant difference was observed
between siGLO (1d – 720.25 +/- 69.01 x10-6mm2/sec; 3d – 690.11 +/- 57.56 x106

mm2/sec) and siCx43 (1d – 763.56 +/- 38.25 x10-6mm2/sec; 3d – 766.65 +/- 61.93 x10-

6

mm2/sec) (Fig. 8C). No significant difference was observed in the ipsilateral

hippocampus either between siGLO (1d – 708.02 +/- 62.70 x10-6mm2/sec; 3d – 703.98
+/- 70.18 x10-6mm2/sec) and siCx43 (1d – 769.96 +/- 59.07 x10-6mm2/sec; 3d – 815.10
+/- 91.68 x10-6mm2/sec) (Fig. 8D).
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Figure 8. Significant difference in T2 and ADC was not Observed Acutely between
siCx43 and Control. The extent of edema formation was assessed via MRI using T2
(water content) and ADC (water mobility). The T2 value did not significantly differ
between siCx43 and siGLO pups within the (A) perilesional cortex or (B) ipsilateral
hippocampus at neither 1d nor 3d (B). The ADC value did not significantly differ
between siCx43 and siGLO pups within the (C) perilesional cortex or (D) ipsilateral
hippocampus at neither 1d nor 3d. This most likely signifies that siCx43 did not result in
changes in the edema formation after jTBI.
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Discussion
Our novel study is the first to characterize the changes in Cx43 and Cx30 proteins
after jTBI and also to assess the effect of a post injury administration of siCx43 in a
model of jTBI during the acute period.
Cx30 and Cx43 were increased in the perilesional cortex and ipsilateral CA1 after
jTBI, although in a different pattern. GFAP was also used to assess the extent of
astrogliosis after jTBI, and was observed to be increased after jTBI as well.
siCx43 treatment after jTBI resulted in an improved neurobehavioral outcome and
decreased reactive astrogliosis, resulting from a decreased Cx43 level. To the best of our
knowledge, this is the first study to use neurobehavioral test as an outcome assessor after
specific inhibition of Cx43 in a TBI model.

Changes Seen in Astrocytic Connexins after jTBI
Astrocytes form a network in which individual astrocytes connect with each other,
allow neurotransmitter and ionic flow, and influence each other and the network as a
whole. Appropriately, the term, astrocyte network (Giaume et al., 2010) is frequently
used to describe this characteristic in which astrocytes are interconnected with each other
through gap junctions that are made of connexin proteins: predominantly connexin 43,
and also connexin 30, that facilitate intercellular communication (Giaume et al., 2010;
Seifert et al., 2006). Despite this interest, there is yet much more to be studied for the
ultimate goal of finding therapeutics for those suffering from presently untreatable or
incurable cerebral dysfunctions. Astrocytes and the network they form are essential for
normal brain function, and disruption of this network due to traumatic brain injury leads
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to pathological cascades such as excitotoxicity, apoptosis, neuroinflammation, and edema
(Fukuda et al., 2012a; Kimelberg, 2005; Woodcock and Morganti-Kossmann, 2013;
Zhang et al., 2006). In the brain, the main astrocytic gap junction forming proteins are
connexin 43 and connexin 30 (Nagy et al., 2004).
Although Cx43 and Cx30 are both the main astrocytic connexin proteins,
especially in the perivascular endfeet, the pattern of change was different between the
two proteins, where Cx30 was acutely increased after injury but Cx43 was decreased
initially, and upregulated chronically afterwards. In terms of edema, it is interesting to
note that Cx30 is increased but Cx43 is not during the edema formation phase (1d), both
Cx30 and Cx43 is increased during the peak of edema (3d) and only Cx43 is increased
during the edema resorption phase (7d). In a model of stab wound injury, Cx43 showed
an increase after injury but Cx30 did not (Theodoric et al., 2012). A model of neonatal
cerebral hypoxia ischemia injury also showed different changes in expression pattern of
the two proteins, in which Cx30 showed a slight increase acutely then normalized,
whereas Cx43 protein levels did not change after injury (Zeinieh et al., 2010).
Thus, acutely, the expression profile of Cx43 follows that of AQP4 as we
previously described (Fukuda et al., 2012a), where a slight initial decrease, although not
significant, at 1d is observed, followed by an increase at 3d and 7d (Fig 1). However,
Cx43 was observed to still be increased even at 60d, whereas AQP4 was not. In contrast
there is increased Cx30 levels starting from 1d, and maintained up to 3d (Fig 3), but not
until 7d. This might signify that AQP4 and Cx43 may have a functional role together
during the acute period. Accordingly, in astrocyte cell cultures, AQP4 downregulation led
to decreased expression of Cx43 (Nicchia et al., 2005), and in a transgenic mice lacking
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Cx43 and Cx30, decreased expression of AQP4 was observed (Ezan et al., 2012). Thus,
Cx43 follows the pattern of AQP4, and may be contributing to the edema resorption at 7d
after injury as speculated previously (Fukuda et al., 2012b).
Increased connexins after injury has been proposed to be detrimental in several
studies (Chew et al., 2010), but some have speculated connexins to be beneficial as well
and there is no universal consensus (Andrade-Rozental et al., 2000; Farahani et al., 2005;
Perez Velazquez et al., 2003). In adult models of TBI using a lateral fluid percussion
injury model in adult rats, a similar pattern of Cx43 immunoreactivity was seen as our
model of jTBI in which an initial reduction was followed by an increase in the
hippocampus and the cortex (Ohsumi et al., 2006). However, it is interesting to note that
this acute reduction was observed at 6h, and the immunoreactivity started to increase at
24 hours (Ohsumi et al., 2006). This apparent shift of the time course of events may be
due to a different injury model and/or different age, highlighting the importance of
treating jTBI as a different pathology than adult TBI (Giza et al., 2007; Kochanek, 2006).
Thus, it is most likely that the determining factors of whether connexin overexpression is
beneficial or detrimental are the injury type and the timepoint after injury. Indeed it is
possible that the connexins may have different functional roles during the acute and
chronic phase after injury. And it is possible that the increased level of Cx43 could be
beneficial during certain timepoints but not at others; as hypothesized for AQP4 where
inhibition of AQP4 would be beneficial during the edema formation phase, but not during
the edema resolution phase (Fukuda et al., 2012a; Fukuda et al., 2013).
We hypothesized that astrocytes most likely play a multi-faceted role in the
edema process because of Cx43 and AQP4. First, via a key protein expressed in the
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perivascular astrocyte endfeet, aquaporin 4 (AQP4), a member of the water channel
proteins expressed abundantly in the brain that permit water entry into the brain across
the BBB. Second, through the astrocyte network, which facilitates intercellular
communication through gap junction channels formed mainly by connexin 43 (Cx43)
proteins, allowing the spread of water accumulation from the primary injured astrocytes
to surrounding cells, causing them to swell as well. Furthermore, non-gap junction
forming hemichannels may have an additional effect via excitotoxicity through
extracellular signaling of ATP and glutamate (Bennett et al., 2012; Kar et al., 2012).
In order to test the hypothesis of whether decreasing Cx43 after jTBI would result
in decreased edema leading to improved recovery, we injected siCx43 after jTBI to assess
the effect.

The Effect of siCx43 Injection after jTBI
We observed a decrease in GFAP immunoreactivity after siCx43 injection after
jTBI (Fig. 7). This decrease in GFAP is in accordance with the aforementioned adult TBI
study with the AS-ODN pretreatment (Wu et al., 2013) and another study in which gap
junction inhibitors, carbenoxolone and octanol, was administered in adult rats that
underwent a needle stab wound to mimic brain injury (Andersson et al., 2011). Although
the exact function and implication of changes in GFAP immunoreactivity is debated, it is
commonly regarded to be associated with reactive astrogliosis (Kimelberg, 2005;
Sofroniew, 2009; Sofroniew and Vinters, 2010). Some evidences suggest that reactive
astrogliosis may contribute to worsened secondary injury depending on the timepoint and
injury model (Laird et al., 2008). In order to study the edema process, magnetic
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resonance imaging (MRI) was used. Because diffusion weighted imaging (DWI) and T2weighted imaging is routinely used as a measure of edema in clinics (Chastain et al.,
2009; Galloway et al., 2008; Hou et al., 2007), and we routinely use it in juvenile animals
(Badaut et al., 2007; Badaut et al., 2011; Fukuda et al., 2012a; Fukuda et al., 2013), it was
used to map out the time course of the evolution of edema. Apparent diffusion coefficient
(ADC) is a DWI parameter which can be thought of as a measure of cerebral water
mobility and T2 can be thought of as cerebral water content. In a previous study using
siAQP4, both ADC and T2 were decreased in jTBI animals injected with siAQP4,
signifying decreased edema, which was associated with improved behavior outcome and
decreased reactive astrogliosis (Fukuda et al., 2013). Thus it was hypothesized that the
inhibition of edema and suppression of secondary injury spread by limiting water
diffusion through the astroglial network as a whole could be achieved by either blocking
water channels (astrocyte-BBB) or gap junctions (astrocyte-astrocyte communication).
However, contrary to our initial hypothesis, post-injury administration of siCx43 did not
result in a significant decrease in edema or BBB disruption.
There are several possible explanations for this observation. First, there is a
possibility that both Cx43 and Cx30 (another astrocytic connexin) must be knocked down
in order to decrease edema. Indeed, it is very plausible that water is still being propagated
across the astrocyte network from the primary injury site to secondary injury sites
through Cx30, compensating for the downregulated Cx43 channels; leading to no
significant observable difference in water content or mobility. Second, pre-treatment/preconditioning seems to yield a greater difference between treatment and control group, as
seen in two studies which showed that pre-treating the animals with a gap junction
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inhibitor resulted in a larger difference between the control than post-treatment
(Andersson et al., 2011; Perez Velazquez et al., 2006). Thus, AS-ODN Cx43 may have
resulted in decreased edema due to the pre-injury injection of the drug. Third, Cx43 in
juvenile animals may not be a key player for the edema process. Water propagation or
clearance may be a function that is more central to other astrocytic proteins, namely the
AQP4 (Badaut et al., 2011). And it is entirely possible that a combination of the above
given explanations may be true. Indeed, a conditional double knockout mice of astrocytic
Cx43 and Cx30 was shown to have weaker BBB and astrocyte endfeet swelling (Ezan et
al., 2012). Also in a model of global ischemia on sheep, Cx43 inhibition through a
specific mimetic peptide was shown to result in increased neuronal and oligodendrocyte
cell count if the peptide was given after the ischemia, but not before and during ischemia
(Davidson et al., 2013).
Although TBI studies on astrocytic Cx43 is sparse, increased Cx43 has been
associated with post-injuries in other brain pathology as well (Chew et al., 2010).
Furthermore, studies of other cerebropathologies such as ischemic stroke have reported
beneficial results from the specific inhibition of Cx43 in vitro (Chew et al., 2010), and
general gap junction inhibition in vivo (Andersson et al., 2011; Perez Velazquez et al.,
2006; Rawanduzy et al., 1997). This may be due to the inhibition of a proposed
phenomenon known as the “bystander effect.” The bystander effect refers to the
hypothesized spread of detrimental factors and toxic metabolites such as sodium and
calcium ions, apoptotic factors, lysophospholipids, cAMP, and IP3 from the primary
injury site to more distant sites mediated by gap junctions connecting the astrocyte
network (Andrade-Rozental et al., 2000; Cronin et al., 2008; Grange-Messent and
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Bouchaud, 1994; Perez Velazquez et al., 2003). Thus, siCx43 may be a unique and useful
new technical approach to study the in vivo Cx43 involvement as well as a potential
therapeutic tool in other brain injury models as well. However, it is interesting to note
that in models of cerebral hemorrhage, detrimental effects for general gap junction
inhibitors such as carbenoxolone and octanol have been reported: intracerebral
hemorrhage (Manaenko et al., 2009) and experimental subarachnoid hemorrhage (Ayer et
al., 2010). As proposed by the authors, these brain hemorrhages may follow a different
pathway than TBI and stroke – namely that the detrimental factors are extracellular, and
the intra-astrocellular bridges formed by gap junctions may not be as important (Ayer et
al., 2010).
In conclusion, we show here for the first time the temporal changes in Cx43,
Cx30, and GFAP after jTBI. We also show that siCx43 injection after injury on juvenile
animal results in improved sensorimotor, coordination, and balance recovery, associated
with decreased Cx43 and reactive astrogliosis, but is not associated with the edema
formation process. Future studies could further examine the affected pathways underlying
the beneficial effects such as decreased cell death, neuroinflammation, or decreased
excitotoxicity.
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CHAPTER FIVE
DISCUSSION
Parts of the following work has been published in the peer reviewed journal,
Biochimica et Biophysica Acta, 2014 May;1840(5):1554-65.

Aquaporin and Brain Diseases
Edema Process: Role of the Aquaporins
Most brain diseases (e.g. stroke, traumatic brain injury, brain tumors, brain
inflammation) present the hallmark of edema, which is water accumulation resulting from
brain osmotic homeostasis dysfunctions. The main consequence of edema is the swelling
of the brain, which aggravates the secondary injuries such as decrease of brain perfusion.
Edema has been known in the clinic and pre-clinical science for many years but the
molecular and cellular events in edema formation/resolution are still poorly understood.
Moreover, there is no efficient treatment to prevent or limit edema formation or
expansion in brain disorders. Thus, the discovery of the brain AQPs was a beacon of
hope in the development of new therapy to battle the edema process. The knowledge
gathered in the past 15 years on AQPs as a potential drug target for edema is summarized
in the following parts after a short introduction on the edema build-up phase.
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Edema Build-Up Phase: Anoxic, Ionic
and Vasogenic Edema
For 40 years, cerebral edema has been traditionally divided into 2 major classes:
cytotoxic and vasogenic (Badaut et al., 2011b). Classically, cytotoxic edema is defined by
intracellular water accumulation without blood-brain barrier (BBB) disruption while
vasogenic edema appears after BBB disruption, leading to a diffusion of proteins from
the blood to the tissue followed by water accumulation in the extracellular space (Badaut
et al., 2011b). However, this classical subdivision has been challenged by the recent
knowledge in molecular changes during the edema formation and BBB properties, and
the classical subdivision represents a simplified view of a more complex pathological
process. In regard to vascular brain injuries such as jTBI, the recent cellular and
molecular events behind edema suggest that the edema build-up phase can be divided
into 3 major types: anoxic, ionic and vasogenic edema (Simard et al., 2007, Badaut et al.,
2011b, Berezowski et al., 2012). Anoxic edema is characterized as swelling of the
astrocytes and neuronal dendrites that occur within minutes (figure 1B) after oxygen and
glucose deprivation in the context of cerebrovascular disease. The depletion of oxygen
and energy nutrients induces major changes in the cellular ionic gradients due to the
absence of efficient energy dependent co-transporters. This leads to a massive entry of
ions into cells which can be observed in phenomenon such as a slow rise in extracellular
K+ concentration (Milner and Campbell, 2002, Dityatev and Schachner, 2003), followed
by water entry into the cells, which induces cellular swelling in astrocytes first, and then
in neuronal dendrites (Figure 1B). Then, anoxic edema quickly evolves to become ionic
edema. The absence of oxygen and nutrients also alters the ionic gradients of endothelial
cells, including transcapillary flux of Na + (O'Donnell et al., 2004, Simard et al., 2007)
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with tissue swelling (Figure 1B). Suffering of endothelial cells therefore results in early
transient leakage of the BBB in stroke (de Castro Ribeiro et al., 2006, Hirt et al., 2009) as
well as in TBI (Pop et al., 2013). This results in further entry of water through endothelial
cells leading to brain swelling as observed from examples in stroke models within 30
minutes after reperfusion (de Castro Ribeiro et al., 2006, Hirt et al., 2009) associated with
further increased BBB permeability (Strbian et al., 2008, Hirt et al., 2009). Vasogenic
edema follows this cascade of events (Figure 1B) with increased permeability to plasma
proteins such as albumin (Badaut et al.) due to a physical disruption of endothelial tight
junctions, an extracellular matrix degradation and potentially an increased
transendothelial cell transport by the transcytosis mechanism.
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Figure 1. Disorganization of AQP4 in orthogonal particles after brain injuries and edema
process. (A) AQP4-m1 (purple circles) and AQP4-m23 (blue circles) isoforms contribute
together to form orthogonal array particles (OAPs) in astrocyte endfeet in contact to the
blood vessels. It was previously shown that higher expression of AQP4-m23 contributes
to the formation of large OAPs. However, increase of AQP4-m1 induced disruption of
OAPs with a reduction of the size. This modification is observed in pathological
conditions such as stroke. Recent knowledge on AQP leads us to hypothesize that the
large OAPs contribute to gas and cation diffusion in the astrocyte membranes through
central pores (green arrows) (modified from [33]). (B) Schematic drawing of the events
happening during edema formation with 3 different edema phases: anoxic, ionic and
vasogenic edema. During the injury with decrease of brain perfusion, the first minutes are
characterized by anoxic edema. Anoxic edema is characterized as a swelling of the
astrocytes and the neuronal dendrites caused by a disruption of the cellular ionic
gradients and the entry of ions followed by water entry and leading to cellular swelling.
During the ionic edema, astrocytes become swollen and neuronal death starts to occur
resulting in shrinkage of the neurons, shear stress and endothelial dysfunctions on the
non-perfused vascular tree, which results in early transient leakage of the BBB.
Vasogenic edema is a result of disruption of the tight junctions between the endothelial
cells, leading to increased permeability of the cerebral blood-vessels to albumin and other
plasma proteins, further contributing to swelling of astrocytes and subsequent neuronal
cell death. (adapted from [33]).
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It is important to mention that this definition was proposed in the context of brain
injuries involving acute cerebrovascular dysfunctions and may not be adequately adapted
for other brain disorders such as brain tumors (Nico and Ribatti, 2011). In this regard, it
is important to underline that clinical treatments solely focusing on osmotic challenges
are not efficient or sufficient for treatment of cerebral edema, because of the suggested
complexity and diversity in the molecular mechanisms underlying the edema formation
process. Although the exact functional contributions of cerebral AQPs are not yet fully
understood, because of their localization and their identity as water channel proteins, they
most likely play vital roles in the cerebral edema process. We will now review the role of
the AQPs within the context of this revised subdivision of edema formation.

AQP4 and Edema Build-Up
Acute brain injuries including trauma (Ke et al., 2001, Fukuda et al., 2012),
ischemia (Meng et al., 2004, de Castro Ribeiro et al., 2006), and subarachnoid
hemorrhage (Badaut et al., 2003), each have distinct patterns of alteration in the level of
AQP4 expression. Early after stroke, AQP4 expression is rapidly up-regulated in the
astrocyte endfeet in contact with blood vessels, peaking at 1h after stroke onset in a
model of transient occlusion of the middle cerebral artery (de Castro Ribeiro et al., 2006,
Hirt et al., 2009). These early changes are associated with the development of ionic brain
edema (Figure 1B) and the swelling of the astrocyte processes in stroke models (Risher et
al., 2009). However, increased AQP4 expression is not observed in more severe stroke
models (Friedman et al., 2009), prompting the hypothesis that under great tissue duress,
the brain is not able to synthesize sufficient new AQP4 proteins during the early phase of
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reperfusion. Interestingly, in stroke, the ratio of AQP4-m1 and AQP4-m23 is changed in
the ischemic hemisphere, with higher induction of AQP4-m1 compared to AQP4-m23
(Hirt et al., 2009), suggesting a disorganization of the OAPs in accordance with previous
rat stroke data (Suzuki et al., 1984). However, the functional consequences of AQP4-m1
increase and disorganization in stroke are not yet elucidated (Figure 1A) and in our jTBI
model there was no significant difference in the ratio between AQP4-m1 compared to
AQP4-m23 between sham and jTBI animals (Fukuda et al., 2012).
The complexity of the role of AQP4 in edema process is outlined by the variety of
the changes in AQP4 expression, which seems to depend on both the degree of severity
and the pathological model. Indeed, increased AQP4 (Sun et al., 2003, Guo et al., 2006,
Ding et al., 2009, Higashida et al., 2011, Tomura et al., 2011) versus decreased AQP4
(Ke et al., 2001, Kiening et al., 2002, Zhao et al., 2005) are likely due to differences in
injury type, rodent strains, and age at impact (Fukuda et al., 2012). Moreover, several
studies using the AQP4-/- mice showed discrepancies in the outcomes and interpretation
of the role of AQP4 in edema process. For example, AQP4-/- mice reveal a protective
role for AQP4 in spinal cord injury models with a decrease of edema formation and
lesion size at early time point after injury (Saadoun et al., 2010). Using a similar model
and transgenic mice, a second set of experiments showed functional improvement for the
WT mice compared to the AQP4-/- mice at longterm after contusion spinal cord injury
(Kimura et al., 2010), suggesting that AQP4 either plays detrimental roles in the edema
process or a protective role by facilitating the clearance of excess water. Several other
contradictory results using the non-conditional AQP4-/- mice (Saadoun et al., 2008,
Kimura et al., 2010), indicate the limitations of using this genetic tool to solve the
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question of the pathophysiological role of AQP4 in edema formation. In our lab, we
recently developed in vivo application of siRNA targeting AQP4 (siAQP4), showing
specific AQP4 decrease with reduced water mobility (Badaut et al., 2011a, Fukuda et al.,
2013, in press). This new tool is further developed as a molecular approach to address the
question of the role of AQP4 in edema formation, which was tested in a model of
juvenile traumatic brain injury (jTBI). In this model we showed that AQP4 expression is
not changed at 24h during the build-up of edema (Fukuda et al., 2012). Our results
suggest that stable AQP4 levels may contribute to water entry leading to cellular swelling
(lower apparent diffusion coefficient (ADC)) and increased edema (increased T2) at
proximity of the site of impact (Fukuda et al., 2012). Interestingly, application of siAQP4
after jTBI induced a reduction in edema formation associated with cognitive
improvement at 2 months post-injury, suggesting that siAQP4 could be used as a specific
drug to prevent edema formation by transiently decreasing the level of AQP4 expression
(Fukuda et al., 2013, in press). This data show that the presence of AQP4 plays a
deleterious role during the edema formation by facilitating the entry of water in the
astrocytes.

Edema Resolution in Acute Brain Disease:
Role of AQP in Water Clearance
As mentioned previously, the data generated using AQP4-/- mice raised the
hypothesis of a dual role for AQP4 in the edema process with a deleterious role of AQP4
in edema build-up and its beneficial role in water clearance during the edema resolution
(Saadoun and Papadopoulos, Papadopoulos et al., 2004). Despite the lack of a clear
answer on the role of AQP4 in edema resolution, several results support this hypothesis.
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The first evidence is the infusion of saline solution in brain parenchyma that induced
significant increase in the intracranial pressure in AQP4-/- mice compared to the WT
(Papadopoulos et al., 2004). In several pathological conditions, increased AQP4 was
observed to be associated with edema resolution measured over time using MRI (Meng et
al., 2004, Tourdias et al., 2009, Badaut et al., 2011a, Badaut et al., 2011b, Tourdias et al.,
2011, Fukuda et al., 2012, Fukuda et al., 2013, in press). Frequently, AQP4 expression is
increased after 48h in stroke models (de Castro Ribeiro et al., 2006, Hirt et al., 2009), in
TBI (Sun et al., 2003, Guo et al., 2006, Ding et al., 2009, Higashida et al., 2011, Tomura
et al., 2011, Fukuda et al., 2012) and in neuroinflammatory lesion conditions (Tourdias et
al., 2011). Most of the time, the increase of the AQP4 is observed near the lesion site in
perivascular astrocyte endfeet, astrocyte processes, and the glia limitans (de Castro
Ribeiro et al., 2006, Fukuda et al., 2012). These changes may indicate that excess AQP4
could facilitate edematous fluid elimination through the subarachnoid space (FernandezTeruel et al., 2002, Nicchia et al., 2009, Tourdias et al., 2011). As observed in a jTBI
model, increased AQP4 in the glia limitans may compensate for water accumulation at 1
and 3 days (higher T2), with a gradual increase of AQP4 at 3 days and normalization of
both AQP4 and T2 values by 7 days (Fukuda et al., 2012). In the rat neuroinflammatory
lesion model, the ADC monitored time course study indicates a clear distinction between
a minor AQP4 expression increase during the edema build-up phase and a shift to strong
AQP4 expression during the edema resolution phase (Tourdias et al., 2011). In fact, ADC
values are significantly increased when AQP4 expression is at the peak of its expression
(Tourdias et al., 2011).
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Neuroinflammation in Brain Injury:
Astrocytic AQP4
AQP4 expression is frequently increased during the onset of neuroinflammatory
period characterized by microglia activation and astrogliosis. In fact, several interesting
recent data suggest a potential relationship between AQP4 and microglial activation,
without a clear definition about the link. First, AQP4-/- mice are more vulnerable to
seizures compared to WT one month after TBI (Lu et al., 2011). This difference was
explained by the neuroinflammatory response showing less astrogliosis and increased
microglial activation in AQP4-/- compared to WT mice. Minocycline injection in AQP4/- reversed the outcome by inhibition of the increase in microglia activation and
decreased the severity of post-traumatic seizures (Lu et al., 2011). Similar results were
reported in cryo-injury models, where AQP4-/- mice presented increased microglia and
reduced astrogliosis compared to WT. In this model, a decrease in the lesion volume and
in neuronal loss in AQP4-/- mice compared to WT was reported at 1 day after injury
whereas the opposite result was reported at 7 and 14 days (Saubamea et al., 2012). In our
lab, we have also observed that the siAQP4 treatment after jTBI showed a decrease in
AQP4 associated with less BBB disruption, less edema, more NeuN positive cells, and
better behavior outcomes compared to the control group up to 2 months post-injury
(Fukuda et al., 2013). As observed in the AQP4-/- mice, we reported an increase in
activated microglia and a decrease in astrogliosis around the lesion at 3 days post-injury
in siAQP4 treated rats compared to control group. However, this difference is not present
anymore at 2 months post-injury (Fukuda et al., 2013). One possible explanation for this
observation may be that changes in AQP4 expression are associated with changes in
astrogliosis and microglia activation in acute brain injury. Astrogliosis may require the
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presence of AQP4 to facilitate the water movement necessary for migration (Saadoun et
al., 2005, Auguste et al., 2007) and hypertrophy. However, the mechanism behind the
decrease of the AQP4 and activation of microglia is still unknown. One possible
mechanism is a modification in the pattern of cytokine release in response to astrocytic
AQP4 down regulation or inhibition. The other hypothesis is in relation with the presence
of stretch-activated chloride (Cl-) channels expressed in microglia and known to be
activated by osmotic stress (Lewis et al., 1993, Eder et al., 1998, Schlichter et al., 2011).
The activation of these channels contributes to the maintenance of the non-activated
(ramified) phenotype of microglia (Eder et al., 1998). Because AQP4 is responsible for
water transport and osmotic pressure, we can hypothesize that inhibition of AQP4 either
through genetic deletion or siRNA will modify the osmotic stress within the extracellular
space surrounding the microglia. This would change the activation status of the swelling
activated chloride channels, resulting in microglia activation. Another possibility lies in
the cross talk that occurs between astrogliosis and microglia activation (Liu et al., 2011).
The decrease of reactive astrogliosis as a result of the absence of AQP4 may cause an
increase in microglial activity. The exact link between microglial activation and
decreased astrogliosis in absence of AQP4 needs further investigation. However, it is
likely that at 3 days post-jTBI, increased microglia activation due to siAQP4 treatment is
contributing to the beneficial effects observed on the cognitive outcome. Indeed, acute
microglia activation was hypothesized to be beneficial in contrast to chronic microglia
activation (Loane and Byrnes, 2010). These changes of AQP4 in relation with
neuroinflammation could also be correlated with imaging signal changes over time after
brain injury or in chronic brain disorders.
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Future Developments: Drugs Against AQP4?
As mentioned previously, there is no specific inhibitor to block the AQP4 channel
and such a compound is critical for evaluating the role of AQP4 and treatment of edema.
Using siRNA strategy permitted to show the potential to use a specific inhibitor of AQP4
in jTBI and the contribution of astrocytic AQP4 in neuroimaging (Manley et al., 2000,
Fukuda et al., 2013, in press). Although non-specific, a range of compounds already
commercially available that may block AQP4 have been tested. Bumetanide blocks the
AQP4 channel and water permeability in oocytes (Migliati et al., 2009), and bumetanide
prevents edema formation after brain ischemia (O'Donnell et al., 2004, Migliati et al.),
which correlates with decreased AQP4 expression (Migliati et al.). However bumetanide
is also an inhibitor of Na-Cl-K co-transporter expressed in endothelial cells. This multiple
site of action of bumetanide is complicating in vivo validation and makes teasing out solo
effects of AQP4 difficult (O'Donnell et al., 2004). Therefore the benefits of bumetanide
on edema could also be due to the inhibition of Na-Cl-K co transporter expressed in
endothelial cells. Acetazolamide (AZA), a sulfonamide carbonic anhydrase inhibitor was
also proposed for a specific inhibitor of water permeability associated with AQP1 and
AQP4 (Huber et al., 2007, Tanimura et al., 2009). However, it was reported that AZA has
no effect on water permeability (Sogaard and Zeuthen, 2008, Yang et al., 2008).
Similarly, two other inhibitors belonging to sulfonamide carbonic anhydrase inhibitor
class, methazolamide and valproic acid have also been tested but without clear effects on
the water permeability (Huber et al., 2009, Tanimura et al., 2009). Waiting to have a
specific pharmacological drug to block AQP4, the siRNA strategy was used with success
in normal brain to silence the AQP4 expression (Badaut et al., 2011a). Decrease of AQP4
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is associated with a decrease of ADC values (Badaut et al., 2011a). siAQP4 was used as
treatment in jTBI with decrease of the edema formation post-TBI and functional
improvement up to 2 months post-injury (Fukuda et al., 2013, in press). These results
encourage us to use the siRNA strategy as a specific drug to prevent the edema
formation. However, heterogeneous alterations in AQP4 expression demonstrate the
complexity of modifying edema reduction. This strongly suggests testing the siAQP4
treatment strategy in different brain disorder models to find out which battles will be won
with siRNA, and which ones should be avoided.

Connexin 43: Consideration of Potential Post Injury
Cascade other than Edema Formation
In our hypothesized model before conducting the studies, AQP4 was thought of as
the initial passage into the astrocyte network entering/exiting the network. Cx43, on the
other hand, was thought to be the passageway between astrocytes within the network. We
thought that siRNA against either protein would decrease edema formation and result in
beneficial outcome after jTBI. However, unlike siAQP4 treatment, siCx43 did not result
in changes in the edema process after jTBI. But although the edema process did not seem
to be altered with siCx43, nevertheless, siCx43 animals did perform better in the foot
fault test compared to control.
Thus we speculate that Cx43 most likely plays a role in the injury cascade of jTBI
other than edema. In order to shed light onto possible non-edematous roles of Cx43, it is
important to consider the functions of non-gap junction forming, or uncoupled,
hemichannels; which do not participate in intracellular trafficking of molecules, but
rather between the astrocyte and the extracellular environment (Goodenough and Paul,
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2003). Eugenin et al. has an excellent review which contains a section on Cx43 astroglial
hemichannels (Eugenin et al., 2012). Under normal condition, uncoupled Cx43
hemichannels remain closed but a variety of pathological triggers such as metabolic
inhibition, fibroblast growth factor 1, hypoxic condition, ischemic condition, oxidative
stress, increased calcium concentration, and acidic environment can open the
hemichannel, leading to release of ATP, glutamate, NADH out to the extracellular space
(Contreras et al., 2002, Bennett et al., 2012, Eugenin et al., 2012, Kar et al., 2012). This
release increases neurotoxicity and neuronal susceptibility to insult, leading to proinflammatory cytokine induced neuronal cell death (Froger et al., 2010, Orellana et al.,
2011). At this point, it is also important to remember that one of the key hallmarks of
injury after brain injury is reactive astrogliosis, which modulates production of proinflammatory cytokines (Anderson et al., 2014). Cx43 KO animal has been shown to
have decreased astrogliosis and decreased proliferation of astrogliosis after ischemia as
well (Nakase et al., 2004). Alas, some pathological functions that have been associated
with Cx43 upregulation are apoptosis, excitotoxicity, and neuroinflammation (Bennett et
al., 2012), and these functions could be explained by opening of uncoupled
hemichannels. In our model, we also observed the siCx43 resulted in a decreased postinjury reactive astrogliosis as interpreted via decreased GFAP immunofluorescence
intensity (Ch. 4). Thus, in future studies, the potential effect of siCx43 after jTBI on other
mechanisms can be studied such as caspase-3 for apoptosis, NeuN for neuronal survival
and IBA for microglial activation as performed in our earlier AQP4 studies (Fukuda et
al., 2013).
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Additionally, it is also important to consider the potential role and function of the
other astrocyte gap junction forming connexin: Cx30. Because Cx30 was discovered in
astrocytes later than Cx43 (Nagy et al., 1997, Nagy et al., 1999), Cx43 has been studied
in more extensive detail than Cx30 as the main astrocyte connexin. Thus, Cx30’s specific
functions in the brain are still largely unknown, although Cx30 has been shown to have a
functional role in controlling cellular membrane integrity in the inner ear (Schutz et al.,
2010, Forge et al., 2013) and glutamate clearance (Pannasch et al., 2014). However, a
study which compared a Cx43 KO to Cx30 KO to a Cx43/30 Double KO showed that the
double KO mice had white matter intramyelinic edema and astrocyte edema in the CA1
but the single allele deletions did not have any edema, potentially signifying that Cx43
and Cx30 may have redundant roles and may compensate each other in situations where
one protein is decreased (Lutz et al., 2009). Additionally Cx43/30 Double KO also
showed a weakened state of BBB as well, which could lead to increased vasogenic edema
under stress and insult such as jTBI (Ezan et al., 2012). Thus, it is possible that Cx43 and
Cx30 both have overlapping roles regarding water homeostasis and the edema process,
therefore siCx43 alone did not cause a change in T2 and ADC value due to Cx30
compensation.
And lastly, future studies can better elucidate the potential relationship that AQP4
and Cx43 and Cx30 may have on each other under normal and pathological conditions.
Interestingly, a decrease in Cx43 protein expression and a concomitant decrease in gap
junction function after administration of siRNA against AQP4 in primary astrocyte
culture have been reported (Nicchia et al., 2005). Another brain cell cultures taken from
AQP4 -/- mice have also shown lower Cx43 protein level compared to wildtype (Kong et
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al., 2008). A transgenic mice lacking Cx43 and Cx30 have also been reported to have
decreased AQP4 levels (Ezan et al., 2012).
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